AU2017249603B2 - Methods of treatment for cholestatic and fibrotic diseases - Google Patents
Methods of treatment for cholestatic and fibrotic diseases Download PDFInfo
- Publication number
- AU2017249603B2 AU2017249603B2 AU2017249603A AU2017249603A AU2017249603B2 AU 2017249603 B2 AU2017249603 B2 AU 2017249603B2 AU 2017249603 A AU2017249603 A AU 2017249603A AU 2017249603 A AU2017249603 A AU 2017249603A AU 2017249603 B2 AU2017249603 B2 AU 2017249603B2
- Authority
- AU
- Australia
- Prior art keywords
- ntz
- fibrosis
- statin
- synergistic combination
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 64
- 230000003176 fibrotic effect Effects 0.000 title claims abstract description 56
- 230000001587 cholestatic effect Effects 0.000 title claims description 29
- 238000000034 method Methods 0.000 title claims description 24
- 238000011282 treatment Methods 0.000 title abstract description 39
- 201000010099 disease Diseases 0.000 title abstract description 29
- 239000011885 synergistic combination Substances 0.000 claims abstract description 38
- YQNQNVDNTFHQSW-UHFFFAOYSA-N acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 claims description 143
- 229960002480 nitazoxanide Drugs 0.000 claims description 132
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 102
- FDTZUTSGGSRHQF-UHFFFAOYSA-N Desacetyl-nitazoxanide Chemical compound OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 FDTZUTSGGSRHQF-UHFFFAOYSA-N 0.000 claims description 72
- 150000001875 compounds Chemical class 0.000 claims description 45
- 206010016654 Fibrosis Diseases 0.000 claims description 36
- 230000004761 fibrosis Effects 0.000 claims description 36
- 208000035475 disorder Diseases 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 32
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 30
- 230000003510 anti-fibrotic effect Effects 0.000 claims description 30
- 229960002855 simvastatin Drugs 0.000 claims description 30
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 30
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims description 29
- 229960003765 fluvastatin Drugs 0.000 claims description 29
- 229960002797 pitavastatin Drugs 0.000 claims description 26
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims description 26
- 230000002195 synergetic effect Effects 0.000 claims description 24
- -1 NTZ-D Chemical compound 0.000 claims description 22
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 20
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 20
- 229960005370 atorvastatin Drugs 0.000 claims description 20
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 19
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 19
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 16
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 15
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 15
- 229960004844 lovastatin Drugs 0.000 claims description 15
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 15
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 15
- 229960002965 pravastatin Drugs 0.000 claims description 15
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 15
- 102000005962 receptors Human genes 0.000 claims description 15
- 108020003175 receptors Proteins 0.000 claims description 15
- 210000004185 liver Anatomy 0.000 claims description 13
- 230000037361 pathway Effects 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 102000004127 Cytokines Human genes 0.000 claims description 12
- 108090000695 Cytokines Proteins 0.000 claims description 12
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 claims description 12
- 210000004072 lung Anatomy 0.000 claims description 11
- 229960000672 rosuvastatin Drugs 0.000 claims description 11
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 11
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 11
- 206010008635 Cholestasis Diseases 0.000 claims description 10
- 230000007870 cholestasis Effects 0.000 claims description 10
- 231100000359 cholestasis Toxicity 0.000 claims description 10
- 210000003734 kidney Anatomy 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 239000013543 active substance Substances 0.000 claims description 9
- 239000003112 inhibitor Substances 0.000 claims description 9
- 210000003205 muscle Anatomy 0.000 claims description 9
- 210000003491 skin Anatomy 0.000 claims description 9
- 210000001185 bone marrow Anatomy 0.000 claims description 8
- 210000002216 heart Anatomy 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 8
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 8
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 8
- 210000004872 soft tissue Anatomy 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 7
- 230000001684 chronic effect Effects 0.000 claims description 7
- 102000006495 integrins Human genes 0.000 claims description 7
- 108010044426 integrins Proteins 0.000 claims description 7
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 7
- 230000011664 signaling Effects 0.000 claims description 7
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 6
- 206010010317 Congenital absence of bile ducts Diseases 0.000 claims description 6
- 102000013446 GTP Phosphohydrolases Human genes 0.000 claims description 6
- 108091006109 GTPases Proteins 0.000 claims description 6
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 claims description 6
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims description 6
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 6
- 201000005271 biliary atresia Diseases 0.000 claims description 6
- 208000003167 cholangitis Diseases 0.000 claims description 6
- 230000007705 epithelial mesenchymal transition Effects 0.000 claims description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 230000000968 intestinal effect Effects 0.000 claims description 6
- 210000001370 mediastinum Anatomy 0.000 claims description 6
- 230000000770 proinflammatory effect Effects 0.000 claims description 6
- 210000000574 retroperitoneal space Anatomy 0.000 claims description 6
- 230000019491 signal transduction Effects 0.000 claims description 6
- 101000659879 Homo sapiens Thrombospondin-1 Proteins 0.000 claims description 5
- 102100036034 Thrombospondin-1 Human genes 0.000 claims description 5
- UJTOVSZPBVTOMC-QKZHPOIUSA-N Tizoxanide glucuronide Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 UJTOVSZPBVTOMC-QKZHPOIUSA-N 0.000 claims description 5
- 210000004100 adrenal gland Anatomy 0.000 claims description 5
- 210000001367 artery Anatomy 0.000 claims description 5
- 210000003445 biliary tract Anatomy 0.000 claims description 5
- 210000000845 cartilage Anatomy 0.000 claims description 5
- 210000001072 colon Anatomy 0.000 claims description 5
- 230000001419 dependent effect Effects 0.000 claims description 5
- 210000002615 epidermis Anatomy 0.000 claims description 5
- 210000000936 intestine Anatomy 0.000 claims description 5
- 210000000653 nervous system Anatomy 0.000 claims description 5
- 210000001672 ovary Anatomy 0.000 claims description 5
- 210000000496 pancreas Anatomy 0.000 claims description 5
- 210000000813 small intestine Anatomy 0.000 claims description 5
- 210000002784 stomach Anatomy 0.000 claims description 5
- 210000002435 tendon Anatomy 0.000 claims description 5
- 210000001550 testis Anatomy 0.000 claims description 5
- 210000004291 uterus Anatomy 0.000 claims description 5
- 210000003462 vein Anatomy 0.000 claims description 5
- 108010059616 Activins Proteins 0.000 claims description 4
- 102000005862 Angiotensin II Human genes 0.000 claims description 4
- 101800000733 Angiotensin-2 Proteins 0.000 claims description 4
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 4
- 102100031168 CCN family member 2 Human genes 0.000 claims description 4
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 claims description 4
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims description 4
- 102000005856 Inhibitory Smad Proteins Human genes 0.000 claims description 4
- 108010005239 Inhibitory Smad Proteins Proteins 0.000 claims description 4
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 4
- 102000043136 MAP kinase family Human genes 0.000 claims description 4
- 108091054455 MAP kinase family Proteins 0.000 claims description 4
- 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 claims description 4
- 108091007960 PI3Ks Proteins 0.000 claims description 4
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims description 4
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims description 4
- 206010050207 Skin fibrosis Diseases 0.000 claims description 4
- 239000012190 activator Substances 0.000 claims description 4
- 239000000488 activin Substances 0.000 claims description 4
- 229950006323 angiotensin ii Drugs 0.000 claims description 4
- 230000008777 canonical pathway Effects 0.000 claims description 4
- 102000034356 gene-regulatory proteins Human genes 0.000 claims description 4
- 108091006104 gene-regulatory proteins Proteins 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 239000000893 inhibin Substances 0.000 claims description 4
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims description 4
- 229960004378 nintedanib Drugs 0.000 claims description 4
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 claims description 4
- 230000008779 noncanonical pathway Effects 0.000 claims description 4
- 229960003073 pirfenidone Drugs 0.000 claims description 4
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 230000008410 smoothened signaling pathway Effects 0.000 claims description 4
- 229960003787 sorafenib Drugs 0.000 claims description 4
- 108091008743 testicular receptors 4 Proteins 0.000 claims description 4
- 201000011374 Alagille syndrome Diseases 0.000 claims description 3
- 206010058029 Arthrofibrosis Diseases 0.000 claims description 3
- 208000033116 Asbestos intoxication Diseases 0.000 claims description 3
- 208000015163 Biliary Tract disease Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 3
- 108010036949 Cyclosporine Proteins 0.000 claims description 3
- 206010014561 Emphysema Diseases 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 3
- 208000024934 IgG4-related mediastinitis Diseases 0.000 claims description 3
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims description 3
- 208000002260 Keloid Diseases 0.000 claims description 3
- 206010023330 Keloid scar Diseases 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims description 3
- 208000002805 Mediastinal fibrosis Diseases 0.000 claims description 3
- ZZIKIHCNFWXKDY-UHFFFAOYSA-N Myriocin Natural products CCCCCCC(=O)CCCCCCC=CCC(O)C(O)C(N)(CO)C(O)=O ZZIKIHCNFWXKDY-UHFFFAOYSA-N 0.000 claims description 3
- 208000003510 Nephrogenic Fibrosing Dermopathy Diseases 0.000 claims description 3
- 206010067467 Nephrogenic systemic fibrosis Diseases 0.000 claims description 3
- 208000012347 Parenteral nutrition associated liver disease Diseases 0.000 claims description 3
- 208000033147 Parenteral nutrition-associated cholestasis Diseases 0.000 claims description 3
- 206010034464 Periarthritis Diseases 0.000 claims description 3
- 201000002150 Progressive familial intrahepatic cholestasis Diseases 0.000 claims description 3
- 208000012619 Progressive familial intrahepatic cholestasis type 3 Diseases 0.000 claims description 3
- 206010036805 Progressive massive fibrosis Diseases 0.000 claims description 3
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 claims description 3
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims description 3
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims description 3
- 206010039710 Scleroderma Diseases 0.000 claims description 3
- 229940127530 Sphingosine 1-Phosphate Receptor Modulators Drugs 0.000 claims description 3
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 3
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 3
- 108091008874 T cell receptors Proteins 0.000 claims description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 claims description 3
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 claims description 3
- 206010003441 asbestosis Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 3
- 229960002170 azathioprine Drugs 0.000 claims description 3
- 229960005110 cerivastatin Drugs 0.000 claims description 3
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims description 3
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 3
- 201000001883 cholelithiasis Diseases 0.000 claims description 3
- 229960001265 ciclosporin Drugs 0.000 claims description 3
- 229960004397 cyclophosphamide Drugs 0.000 claims description 3
- 108010057085 cytokine receptors Proteins 0.000 claims description 3
- 102000003675 cytokine receptors Human genes 0.000 claims description 3
- 201000010048 endomyocardial fibrosis Diseases 0.000 claims description 3
- 208000019298 familial intrahepatic cholestasis Diseases 0.000 claims description 3
- 229960000556 fingolimod Drugs 0.000 claims description 3
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims description 3
- 150000002224 folic acids Chemical class 0.000 claims description 3
- 239000003862 glucocorticoid Substances 0.000 claims description 3
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- 230000002458 infectious effect Effects 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 3
- 201000002161 intrahepatic cholestasis of pregnancy Diseases 0.000 claims description 3
- 210000001117 keloid Anatomy 0.000 claims description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 3
- 229960001428 mercaptopurine Drugs 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 229950009116 mevastatin Drugs 0.000 claims description 3
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims description 3
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims description 3
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical class OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims description 3
- 206010028537 myelofibrosis Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- ZZIKIHCNFWXKDY-GNTQXERDSA-N myriocin Chemical compound CCCCCCC(=O)CCCCCC\C=C\C[C@@H](O)[C@H](O)[C@@](N)(CO)C(O)=O ZZIKIHCNFWXKDY-GNTQXERDSA-N 0.000 claims description 3
- 230000001613 neoplastic effect Effects 0.000 claims description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 3
- 210000003899 penis Anatomy 0.000 claims description 3
- 201000002148 progressive familial intrahepatic cholestasis 3 Diseases 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 150000003212 purines Chemical class 0.000 claims description 3
- 150000003230 pyrimidines Chemical class 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 3
- 208000023504 respiratory system disease Diseases 0.000 claims description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 3
- 229960002930 sirolimus Drugs 0.000 claims description 3
- 229940037128 systemic glucocorticoids Drugs 0.000 claims description 3
- 229960001967 tacrolimus Drugs 0.000 claims description 3
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 3
- 235000021476 total parenteral nutrition Nutrition 0.000 claims description 3
- 201000008827 tuberculosis Diseases 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 102000005606 Activins Human genes 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 34
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 28
- 210000003995 blood forming stem cell Anatomy 0.000 description 21
- 230000005764 inhibitory process Effects 0.000 description 20
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 17
- 230000004913 activation Effects 0.000 description 16
- 210000002950 fibroblast Anatomy 0.000 description 12
- 210000000651 myofibroblast Anatomy 0.000 description 12
- 239000011159 matrix material Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 10
- 239000003613 bile acid Substances 0.000 description 10
- 239000004006 olive oil Substances 0.000 description 10
- 235000008390 olive oil Nutrition 0.000 description 10
- 238000007619 statistical method Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 9
- 230000037213 diet Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 208000024172 Cardiovascular disease Diseases 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 238000000692 Student's t-test Methods 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000002207 metabolite Substances 0.000 description 7
- VWFJDQUYCIWHTN-YFVJMOTDSA-N 2-trans,6-trans-farnesyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-YFVJMOTDSA-N 0.000 description 6
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
- VWFJDQUYCIWHTN-UHFFFAOYSA-N Farnesyl pyrophosphate Natural products CC(C)=CCCC(C)=CCCC(C)=CCOP(O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-UHFFFAOYSA-N 0.000 description 6
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 6
- 206010067125 Liver injury Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 102000009618 Transforming Growth Factors Human genes 0.000 description 6
- 108010009583 Transforming Growth Factors Proteins 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 231100000753 hepatic injury Toxicity 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- OINNEUNVOZHBOX-XBQSVVNOSA-N Geranylgeranyl diphosphate Natural products [P@](=O)(OP(=O)(O)O)(OC/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)O OINNEUNVOZHBOX-XBQSVVNOSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000002202 anti-cholestatic effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000002808 connective tissue Anatomy 0.000 description 5
- 235000020940 control diet Nutrition 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 229910052805 deuterium Inorganic materials 0.000 description 5
- 125000004431 deuterium atom Chemical group 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 210000004024 hepatic stellate cell Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- OINNEUNVOZHBOX-QIRCYJPOSA-K 2-trans,6-trans,10-trans-geranylgeranyl diphosphate(3-) Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\COP([O-])(=O)OP([O-])([O-])=O OINNEUNVOZHBOX-QIRCYJPOSA-K 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000009795 fibrotic process Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 3
- 238000010152 Bonferroni least significant difference Methods 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102100026818 Inhibin beta E chain Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 101710182361 Pyruvate:ferredoxin oxidoreductase Proteins 0.000 description 3
- 230000002141 anti-parasite Effects 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000004500 stellate cell Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- MDBGGTQNNUOQRC-UHFFFAOYSA-N Allidochlor Chemical compound ClCC(=O)N(CC=C)CC=C MDBGGTQNNUOQRC-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000010123 anthracosis Diseases 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000003096 antiparasitic agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000013 bile duct Anatomy 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000006122 isoprenylation Effects 0.000 description 2
- 150000002596 lactones Chemical group 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 2
- 206010035653 pneumoconiosis Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- CXONXVMMINSQBV-NNYOXOHSSA-N (2r,3r,4s,5r)-5-[[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxymethyl]-2-(3-carbamothioylpyridin-1-ium-1-yl)-4-hydroxyoxolan-3-olate Chemical compound NC(=S)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)[O-])=C1 CXONXVMMINSQBV-NNYOXOHSSA-N 0.000 description 1
- DRCLPFURMHGQPC-VIFPVBQESA-N (2s)-2-amino-3-[2-(2-carboxyethyl)-5-chloro-4-nitrophenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC(Cl)=C([N+]([O-])=O)C=C1CCC(O)=O DRCLPFURMHGQPC-VIFPVBQESA-N 0.000 description 1
- KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 description 1
- JTGHBEFBQXGABE-UHFFFAOYSA-N 2,2-dihydroxyheptanoic acid Chemical compound CCCCCC(O)(O)C(O)=O JTGHBEFBQXGABE-UHFFFAOYSA-N 0.000 description 1
- VYHYOBXBZHCQHS-UHFFFAOYSA-N 2-[2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 VYHYOBXBZHCQHS-UHFFFAOYSA-N 0.000 description 1
- CDVAIHNNWWJFJW-UHFFFAOYSA-N 3,5-diethoxycarbonyl-1,4-dihydrocollidine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C CDVAIHNNWWJFJW-UHFFFAOYSA-N 0.000 description 1
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000011068 Cdc42 Human genes 0.000 description 1
- 108050001278 Cdc42 Proteins 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 229920002911 Colestipol Polymers 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 229940124602 FDA-approved drug Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000224467 Giardia intestinalis Species 0.000 description 1
- 244000060234 Gmelina philippensis Species 0.000 description 1
- 102000014015 Growth Differentiation Factors Human genes 0.000 description 1
- 108010050777 Growth Differentiation Factors Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000637835 Homo sapiens Serum amyloid A-4 protein Proteins 0.000 description 1
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 1
- 102000011145 Hydroxysteroid Dehydrogenases Human genes 0.000 description 1
- 108010062875 Hydroxysteroid Dehydrogenases Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 206010072877 Intestinal fibrosis Diseases 0.000 description 1
- 206010023421 Kidney fibrosis Diseases 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 238000013232 NAFLD rodent model Methods 0.000 description 1
- 238000013231 NASH rodent model Methods 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 102100032016 Serum amyloid A-4 protein Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940054685 alinia Drugs 0.000 description 1
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 229940096699 bile acid sequestrants Drugs 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000009787 cardiac fibrosis Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960002604 colestipol Drugs 0.000 description 1
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002603 extrahepatic bile duct Anatomy 0.000 description 1
- 208000009866 extrahepatic cholestasis Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000006506 pH homeostasis Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 230000002206 pro-fibrotic effect Effects 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 244000000040 protozoan parasite Species 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 108700005467 recombinant KCB-1 Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 102000007268 rho GTP-Binding Proteins Human genes 0.000 description 1
- 108010033674 rho GTP-Binding Proteins Proteins 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 108060007624 small GTPase Proteins 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Fish Paste Products (AREA)
- Manufacturing Of Steel Electrode Plates (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a synergistic combination of active ingredients for use in the treatment of fibrotic diseases.
Description
METHODS OF TREATMENT FOR CHOLESTATIC AND FIBROTIC DISEASES
TECHNICAL FIELD
The present invention relates to the field of medicine, in particular to the treatment of cholestatic or fibrotic diseases.
BACKGROUND
Abnormal and exaggerated deposition of extracellular matrix is the hallmark of all fibrotic diseases, including liver, pulmonary, kidney or cardiac fibrosis. The spectrum of affected organs, the progressive nature of the fibrotic process, the large number of affected persons, and the absence of effective treatment pose an enormous challenge when treating fibrotic diseases.
In an attempt to propose new therapeutic strategies for the treatment of fibrotic diseases, the inventors found that 2-[(5-nitro-1 ,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide - NTZ), a synthetic antiprotozoal agent or its deuterated derivatives or its active metabolite 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide, known as TZ) in combination with statins show synergistic antifibrotic activities. Moreover, the evaluation of NTZ combined to a statin in a liver injury model revealed its capacity to reduce circulating bile acid concentration, thus reflecting the synergistic potential of this combination to treat both cholestatic (such as PBC and PSC) and fibrotic diseases.
NTZ, first described in 1975 (Rossignol and Cavier, 1975), was shown to be highly effective against anaerobic protozoa, helminths, and a wide spectrum of microbes including both anaerobic and aerobic bacteria (Rossignol and Maisonneuve, 1984; Dubreuil, Houcke et al., 1996; Megraudd, Occhialini et al., 1998; Fox and Saravolatz, 2005; Pankuch and Appelbaum, 2006; Finegold, Molitoris et al., 2009). It was first studied in humans for the treatment of intestinal cestodes (Rossignol and Maisonneuve, 1984) and it is now licensed in the United States (Alinia®, Romark laboratories) for the treatment of diarrhea caused by the protozoan parasites Crystosporidium parvum and Giardia intestinalis. NTZ has also been widely commercialized in Latin America and in India where it is indicated for treating a broad spectrum of intestinal parasitic infections (Hemphill, Mueller et al., 2006). The proposed mechanism of action by which NTZ exerts its antiparasitic activity is through the inhibition of pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reactions that are essential for anaerobic metabolism (Hoffman, Sisson et al., 2007). NTZ also exhibited activity against Mycobacterium tuberculosis, which does not possess a homolog of PFOR, thus suggesting an alternative mechanism of action. Indeed, the authors showed that
NTZ can also act as an uncoupler disrupting membrane potential and intra-organism pH homeostasis. (de Carvalho, Darby et al., 201 1 ).
The pharmacological effects of NTZ are not restricted to its antiparasitic or antibacterial activities and in recent years, several studies revealed that NTZ can also confer antiviral activity (Di Santo and Ehrisman, 2014; Rossignol, 2014). NTZ interferes with the viral replication by diverse ways including a blockade in the maturation of hemagglutinin (influenza) or VP7 (rotavirus) proteins, or the activation of the protein PKR involved in the innate immune response (for a review, see (Rossignol, 2014)). NTZ was also shown to have broad anticancer properties by interfering with crucial metabolic and prodeath signaling pathways (Di Santo and Ehrisman, 2014).
Statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) are commonly prescribed as medications for the treatment of hypercholesterolemia and for the prevention of cardiovascular disease.
There are currently 7 unique prescribed statins that include pravastatin, simvastatin, and lovastatin (which are naturally-derived from fungal fermentation) and a second group of chemically synthesized statins composed of fluvastatin, atorvastatin, rosuvasatin and pitavastatin. Although all statins contain a dihydroxy-heptanoic acid HMG-CoA like moiety, which competes for binding to HMG-CoA reductase, each statin is unique and exhibits significant differences in chemical structure, potency (ex. IC50 for HMG-CoA reductase inhibition), tissue penetration and retention, half-life, metabolism and elimination, drug-drug interactions, and safety. The mechanisms involved in the beneficial effects of statins on the prevention of cardiovascular disease have been largely attributed to the ability of these agents to inhibit cholesterol biosynthesis. Owing to the fact that 60-70% of serum cholesterol is derived from hepatic biosynthesis and that HMG-CoA reductase is the crucial, rate-limiting enzyme in the cholesterol biosynthetic pathway, it is not surprising that inhibition of this enzyme results in a dramatic reduction in circulating LDL-Cholesterol. Moreover, reduction of LDL-cholesterol leads to upregulation of hepatic LDL receptors and increase of LDL clearance. Both clinical and experimental data suggest that the sum of benefits from statin therapy may extend well beyond their favorable effects on serum cholesterol levels. These cholesterol-independent effects, described as pleiotropic effects of statins, are related to the reduced formation of isoprenoids. Indeed, inhibition of HMG-CoA reductase results not only in deprivation of intracellular mevalonate but also several downstream isoprenoid derivatives including farnesyl pyrophosphate (FPP) and geranylgeranylpyrophosphate(GGPP). Both FPP and GGPP are required for posttranslational prenylation of a number of proteins (approximately 2% of total cellular proteins, (Wang, Liu et al., 2008)). Protein isoprenylation enables proper subcellular localization and trafficking of intracellular molecules. For example,
non-isoprenylated GTPases remain cytosolic whereas isoprenylated GTPases harbour a FPP or GGPP lipid attachment that permits insertion and anchorage into the cell membrane, and subsequently participitate in signal transduction. Therefore, inhibiting isoprenylation results in the inactivation of the small GTPases (ex Rho, Ras, Rac and Cdc42) which are essential in many cellular events (intracellular signal transduction, cellular proliferation, inflammation, motility, (for a review see (McFarlane, Muniyappa et al., 2002; Zhou and Liao, 2009; Yeganeh, Wiechec et al., 2014; Kavalipati, Shah et al., 2015)). Since it has been demonstrated that the Rho GTPase and its target protein Rock are involved in the activation/differentiation of fibroblasts into myofibroblasts (Ji, Tang et al., 2014), a key event in the fibrotic process, several studies were conducted with statins to evaluate their antifibrotic properties in different pathological models. Simvastatin was shown to reduce the expression of fibrotic markers in both human and rat HSC and to confer antifibrotic properties in various animal models of fibrosis (Rombouts, Kisanga et al., 2003; Watts, Sampson et al., 2005; Wang, Zhao et al., 2013; Marrone, Maeso-Diaz et al., 2015). As well, Pitavastatin (Miyaki, Nojiri et al., 201 1 ) and Fluvastatin (Chong, Hsu et al., 2015) were able to reduce fibrosis in the CDAA diet-induced NAFLD/NASH model. These beneficial effects of statins are not restricted to liver fibrosis. Indeed, it was demonstrated that Atorvastatin was significantly potent against bleomycin-induced lung fibrosis (Zhu, Ma et al., 2013) while Simvastatin was shown to inhibit expression of fibrotic markers in fibroblasts derived from human fibrotic lung. (Watts, Sampson et al., 2005).
In this invention, using a phenotypic screening assay to identify potential antifibrotic agents, it was discovered that NTZ or its deuterated derivatives or its active metabolite TZ, in combination with a statin, interferes, in an additive or synergistic manner, with the activation of myofibroblasts. This effect was totally unexpected in view of the properties previously reported for these molecules. Combination of NTZ or its deuterated derivatives or TZ with a specific statin appears as a potent therapeutic strategy for diverse types of fibrotic diseases. Moreover, the evaluation of NTZ or derivatives thereof in combination with a specific statin revealed an unexpected synergistic capacity to reduce circulating bile acid concentration, thus reflecting its potential to treat both cholestatic diseases (such as PBC and PSC) and fibrotic diseases.
SUMMARY OF INVENTION
The present invention relates to a synergistic combination comprising (i) [2-[(5-nitro- 1 ,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (NTZ), a deuterated derivative of NTZ (NTZ-D), 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (TZ), or Tizoxanide glucuronide (TZG)and (ii) at
least one statin. This combination is useful in a method for the treatment of a cholestatic or fibrotic disease.
Therefore, the present invention relates to a synergistic combination of
(i) NTZ, NTZ-D, TZ or TZG, or a pharmaceutically acceptable salt of NTZ, NTZ-D, TZ or
TZG;
(ii) a statin.
The combination of the invention may be in the form of a pharmaceutical composition or of a kit-of-parts.
Furthermore, the components of the synergistic combination of the invention may be administered simultaneously, sequentially and separately.
In a particular embodiment, component (i) of the synergistic combination is NTZ or a pharmaceutically acceptable salt thereof.
In a particular embodiment of the invention, said at least one statin is selected in the group consisting of mevastatin, cerivastatin, pitavastatin, fluvastatin, simvastatin, atorvastatin, lovastatin, rosuvastatin, and pravastatin. In another particular embodiment, the statin is selected in the group consisting of pitavastatin, fluvastatin, simvastatin and atorvastatin. In another particular embodiment, the statin is selected in the group consisting of pitavastatin, fluvastatin and simvastatin.
Furthermore, the synergistic combination of the invention may further comprise at least one therapeutically active agent with known antifibrotic activity selected from pirfenidone or receptor tyrosine kinase inhibitors (RTKIs) such as Nintedanib, Sorafenib and other RTKIs, or angiotensin II (AT1 ) receptor blockers, or CTGF inhibitor, or any antifibrotic compound susceptible to interfere with the TGF3 and BMP-activated pathways including activators of the latent TGF3 complex such as MMP2, MMP9, THBS1 or cell-surface integrins, TGF3 receptors type I (TGFBRI) or type II (TGFBRII) and their ligands such as TGF3, Activin, inhibin, Nodal, anti-Mijllerian hormone, GDFs or BMPs, auxiliary co-receptors
(also known as type III receptors), or components of the SMAD-dependent canonical pathway including regulatory or inhibitory SMAD proteins, or members of the SMAD- independent or non-canonical pathways including various branches of MAPK signaling, TAK1 , Rho-like GTPase signaling pathways, phosphatidylinositol-3 kinase/AKT pathways, TGF3-induced EMT process, or canonical and non-canonical Hedgehog signaling pathways including Hh ligands or target genes, or any members of the WNT, or Notch pathways which are susceptible to influence TGF3 signaling.
Alternatively, the synergistic combination according to the invention may further comprise at least one therapeutically active agent selected from JAK STAT inhibitors and other anti-inflammatory agents and/or immunosuppressant agents. For example, the therapeutically active agent may be selected from glucocorticoids, NSAIDS, cyclophosphamide, nitrosoureas, folic acid analogs, purine analogs, pyrimidine analogs, methotrexate, azathioprine, mercaptopurine, ciclosporin, myriocin, tacrolimus, sirolimus, mycophenolic acid derivatives, fingolimod and other sphingosine-1 -phosphate receptor modulators, monoclonal and/or polyclonal antibodies against such targets as proinflammatory cytokines and proinflammatory cytokine receptors, T-cell receptor and integrins. The present invention also relates to the synergistic combination according to the invention, for use as a medicament.
Furthermore, the invention relates to the synergistic combination described herein, for use in a method for treating a fibrotic disorder. In a particular embodiment, the fibrotic disorder is selected in the group consisting of liver, gut, kidney, skin, epidermis, endodermis, muscle, tendon, cartilage, heart, pancreas, lung, uterus, nervous system, testis, penis, ovary, adrenal gland, artery, vein, colon, intestine (e.g. small intestine), biliary tract, soft tissue (e.g. mediastinum or retroperitoneum), bone marrow, joint, eye and stomach fibrosis. In a further particular embodiment, the fibrotic disorder is selected in the group consisting of liver, kidney, skin, epidermis, endodermis, muscle, tendon, cartilage, heart, pancreas, lung, uterus, nervous system, testis, ovary, adrenal gland, artery, vein, colon, intestine (e.g. small intestine), biliary tract, soft tissue (e.g. mediastinum or retroperitoneum), bone marrow, joint and stomach fibrosis. In a further particular embodiment, the fibrotic disorder is selected in the group consisting of liver, gut, lung, heart, kidney, muscle, skin, soft tissue, bone marrow, intestinal, and joint fibrosis. In yet another embodiment the fibrotic disorder is selected in the group consisting of non-alcoholic steatohepatitis (NASH), pulmonary fibrosis, idiopathic
pulmonary fibrosis, skin fibrosis, eye fibrosis (such as capsular fibrosis), endomyocardial fibrosis, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis (a complication of coal workers' pneumoconiosis), proliferative fibrosis, neoplastic fibrosis, lung fibrosis consecutive to chronic inflammatory airway disease (COPD, asthma, emphysema, smoker's lung,tuberculosis), alcohol or drug-induced liver fibrosis, liver cirrhosis, infection-induced liver fibrosis, radiation or chemotherapeutic-induced fibrosis, nephrogenic systemic fibrosis, Crohn's disease, ulcerative colitis, keloid, old myocardial infarction, scleroderma/systemic sclerosis, arthrofibrosis, some forms of adhesive capsulitis, chronic fibrosing cholangiopathies such as Primary Sclerosing Cholangitis (PSC), Primary Biliary Cholangitis (PBC), biliary atresia, familial intrahepatic cholestasis type 3 (PFIC3), peri- implantational fibrosis and asbestosis.
According to a particular embodiment of the invention, the cholestestatic disease is selected in the group consisting of primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), Intrahepatic Cholestasis of Pregnancy, Progressive Familial Intrahepatic Cholestasis, Biliary atresia, Cholelithiasis, Infectious Cholangitis, Cholangitis associated with Langerhans cell histiocytosis, Alagille syndrome, Nonsyndromic ductal paucity, Drug-induced cholestasis, and Total parenteral nutrition-associated cholestasis. In a particular embodiment, the cholestatic disease is PBC.
According to a particular embodiment, in each aspects and embodiments described herein, NTZ, NTZ-D or TZ, or a pharmaceutically acceptable salt of NTZ; NTZ-D or TZ is used.
DESCRIPTION OF THE FIGURES AND TABLES
Abbreviations used in the figures, in the tables, and in the text:
a-SMA: alpha Smooth Muscle Actin
ATORVA: Atorvastatin
BDL: Bile Duct Ligation
BMP: Bone Morphogenetic Protein
cDNA: Complementary Deoxyribonucleotide acid
COL1A1 : Collagen, type 1 , Alpha 1
CDAA: Choline-Deficient L-Amino Acid
CDAAc: Choline-Deficient L-Amino Acid-defined diet supplemented with cholesterol
CHOL: cholesterol
CSAA: Choline Supplemented L-Amino Acid-defined
DDC: 3,5-diethoxycarbonyl-1 ,4-dihydrocollidine
DMSO: Dimethyl sulfoxide
DTT: Dithiothreitol
ELISA: Enzyme-Linked Immunosorbent Assay
EMT: Epithelial-mesenchymal transition
EOB: Excess Over Bliss
FBS: Fetal Bovine Serum
FDA: Food and Drug Administration
FLUVA: Fluvastatin
FPP: Farnesyl Pyrophosphate
GDF: Growth Differentiation Factors
Hh: Hedgehog
GGPP: Geranylgeranlpyrophosphate
HMG-CoA: 3-hydroxy-3-methylglutaryl-coenzyme A hHSC: Human Hepatic Stellate Cells
HSC: Hepatic Stellate Cells
IC50: Half maximal Inhibitory Concentration
InMyoFib: Intestinal Myofibroblasts
MMP2: Matrix Metallopeptidase 2
MMP9: Matrix Metallopeptidase 9
μΙ: microliter
LDL: Low Density Lipoprotein
LOVA: Lovastatin
NHLF: Normal Human Lung Fibroblasts
NTZ: Nitazoxanide
PBC: Primary Biliary Cholangitis
PBS: Phosphate Buffer Saline
PITA : Pitavastatin
PSC : Primary Sclerosing Cholangitis
qPCR: Quantitative Polymerase Chain Reaction
pMol: picomoles
PRAVA: Pravastatin
rhFGF : recombinant human basic Fibroblast Growth Factor ROSU: Rosuvastatin
RNA: Ribonucleic Acid
RT: Reverse Transcriptase
SIMVA: Simvastatin
SmBM: Smooth Muscle cell Basal Medium
SteCGS: Stellate Cell Growth Supplement
STeCM: Stellate Cell Medium
TBA: Total Bile Acids
TGF i : Tumor Growth Factor beta 1
TGFBRI: TGFb type I receptor
TGFBRII: TGFb type II receptor
THBS1 : Thrombospondine 1
TMB: Tetramethylbenzidine
TZ: Tizoxanide
TZG: Tizoxanide glucuronide
Figure 1 : Nitazoxanide and its metabolite Tizoxanide inhibit TGFS1 -induced expression of o SMA protein in human HSC
Serum-deprived HSC were preincubated for 1 hour with NTZ (A) or TZ (B) before the activation with the profibrogenic cytokine TGF31 (1 ng/ml). After 48 hours of incubation, the expression of a-SMA was measured by ELISA. The obtained values were transformed into percentage inhibition over TGF31 control. Data are presented as mean (triplicates) ± standard deviation (SD). Statistical analyses were performed by one-way ANOVA followed by Bonferroni post-hoc tests, using Sigma Plot 1 1.0 software. [*: p<0.05; **: p<0.01 ; ***: p<0.001 (comparison versus TGF31 1 ng/ml_ group)]. The curve fitting and the calculation of half maximal inhibitory concentration (IC50) were performed with XLFit software 5.3.1 .3.
Figure 2: Differential antifibrotic effect of statin drugs in TGFS-induced hHSC
Serum-deprived hHSC were preincubated for 1 hour with Pitavastatin (A), Fluvastatin (B), Simvastatin (C), Atorvastatin (D), Lovastatin (E), Rosuvastatin (F) and Pravastatin (G) before the activation with the profibrogenic cytokine TGF31 (1 ng/ml). After 48 hours of incubation, the expression of a-SMA was measured by ELISA. The obtained values were transformed into percentage inhibition over TGF31 control. Data are presented as mean (triplicates) ± standard deviation (SD). Statistical analyses were performed by one-way ANOVA followed by Bonferroni post-hoc tests, using Sigma Plot 1 1.0 software. [*: p<0.05; **: p<0.01 ; ***: p<0.001 (comparison versus TGF31 1 ng/mL group)]. The curve fitting and the calculation of half maximal inhibitory concentration (IC50) were performed with XLFit software 5.3.1 .3. Figure 3: Combination of NTZ and Pitavastatin synergistically inhibits a-SMA in TGFpi - induced hHSC
Combinations were tested in a dose-response matrix format and analyzed according to the excess over Bliss (EOB) additivism model. Dilution series of NTZ (column) and Pitavastatin (row) were prepared, including their respective DMSO controls. The resulting mixes were added to serum-deprived HSC, 1 hour prior to the activation with the profibrogenic cytokine TGF31 (1 ng/ml). (A) Percentage of a-SMA inhibition over the TGF31 control for all combination pairs. Data are presented as mean of quadruplicates. (B) EOB scores were calculated as described in Materials and Methods. Any compound pair with positive EOB values was considered synergistic (colored from light grey to black). (C) Data values derived from a synergistic combination pair were plotted in a bar graph representation. Data are presented as mean (quadruplicates) ± standard deviation (SD). Statistical analyses between single agent vs product combination were performed by student t-test or Mann-Whitney Rank Sum Test using Sigma Plot 1 1.0 software. [*: p<0.05; **: p<0.01 ; ***: p<0.001 ].
Figure 4: Combination of NTZ and Simvastatin synergistically inhibits g-SMA in TGFp- induced hHSC
Combinations were tested in a dose-response matrix format and analyzed according to the excess over Bliss (EOB) additivism model. Dilution series of NTZ (column) and Simvastatin (row) were prepared, including their respective DMSO controls. The resulting mixes were added to serum-deprived HSC 1 hour prior to the activation with the profibrogenic cytokine TGF31 (1 ng/ml). (A) Percentage of a-SMA inhibition over the TGF31 control for all combinations. (B) EOB scores were calculated as described in Materials and Methods. Any compound pair with positive EOB values was considered synergistic (colored from light grey to black). (C) Data values derived from a synergistic combination pair were plotted in a bar graph representation. Data are presented as mean (quadruplicates) ± standard deviation (SD). Statistical analyses between single agent vs product combination were performed by student t-test or Mann-Whitney Rank Sum Test using Sigma Plot 1 1.0 software. [*: p<0.05; **: p<0.01 ; ***: p<0.001 ].
Figure 5: Combination of NTZ and Fluvastatin synergistically inhibits a-SMA in TGFp- induced hHSC
Combinations were tested in a dose-response matrix format and analyzed according to the excess over Bliss additivism model. Dilution series of NTZ (column) and Fluvastatin (row) were prepared, including their respective DMSO controls. The resulting mixes were added to serum-deprived HSC, 1 hour prior to the activation with the profibrogenic cytokine TGF31 (1 ng/ml). (A) Percentage of a-SMA inhibition over the TGF31 control for all combinations. (B) Excess over Bliss (EOB) scores were calculated as described in Materials and Methods. Any
compound pair with positive EOB values is considered synergistic (colored from light grey to black), (C) Data values derived from a synergistic combination pair were plotted in a bar graph representation. Data are presented as mean (quadruplicates) ± standard deviation (SD). Statistical analyses between single agent vs product combination were performed by student t-test or Mann-Whitney Rank Sum Test using Sigma Plot 1 1.0 software. [*: p<0.05; **: p<0.01 ; ***: p<0.001 ].
Figure 6: Combination of NTZ and Lovastatin synergistically inhibit ct-SMA in TGFp-induced hHSC
Combinations were tested in a dose-response matrix format and analyzed according to the excess over Bliss additivism model. Dilution series of NTZ (column) and Lovastatin (row) were prepared, including their respective DMSO controls. The resulting mixes were added to serum-deprived HSC 1 hour prior to the activation with the profibrogenic cytokine TGF31 (1 ng/ml). (A) Percentage inhibition of a-SMA over the TGF31 control for all combinations. (B) Excess over Bliss (EOB) scores were calculated as described in Materials and Methods. Any compound pair with positive EOB values is considered synergistic (colored from light grey to blackAn example of a synergistic pair is illustrated in a (C) Data values derived from a synergistic combination pair were plotted in a bar graph representation. Data are presented as mean (quadruplicates) ± standard deviation (SD). Statistical analyses between single agent vs product combination were performed by student t-test or Mann-Whitney Rank Sum Test using Sigma Plot 1 1.0 software. [*: p<0.05; **: p<0.01 ; ***: p<0.001 ].
Figure 7: Combination of NTZ and Atorvastatin synergistically inhibit g-SMA in TGFp-induced hHSC
Combinations were tested in a dose-response matrix format and analyzed according to the excess over Bliss additivism model. Dilution series of NTZ (column) and Atorvastatin (row) were prepared, including their respective DMSO controls. The resulting mixes were added to serum-deprived HSC, 1 hour prior to the activation with the profibrogenic cytokine TGF31 (1 ng/ml). (A) Percentage inhibition of a-SMA over the TGF31 control. (B) Excess over Bliss (EOB) scores were calculated as described in Materials and Methods. Any compound pair with positive EOB values is considered synergistic (colored from light grey to black), (C) Data values derived from a synergistic combination pair were plotted in a bar graph representation. Data are presented as mean (quadruplicates) ± standard deviation (SD). Statistical analyses between single agent vs product combination were performed by student t-test or Mann-Whitney Rank Sum Test using Sigma Plot 1 1 .0 software. [*: p<0.05; **: p<0.01 ; ***: p<0.001 ].
Figure 8: Combination of NTZ and Pravastatin svnergisticallv inhibit a-SMA in TGFp-induced hHSC
Combinations were tested in a dose-response matrix format and analyzed according to the excess over Bliss additivism model. Dilution series of NTZ (column) and Pravastatin (row) were prepared, including their respective DMSO controls. The resulting mixes were added to serum-deprived HSC, 1 hour prior to the activation with the profibrogenic cytokine TGF31 (1 ng/ml). (A) Percentage inhibition of a-SMA over the TGF31 control. (B) Excess over Bliss (EOB) scores were calculated as described in Materials and Methods. Any compound pair with positive EOB values is considered synergistic (colored from light grey to black), (C) Data values derived from a synergistic combination pair were plotted in a bar graph representation. Data are presented as mean (quadruplicates) ± standard deviation (SD). Statistical analyses between single agent vs product combination were performed by student t-test or Mann-Whitney Rank Sum Test using Sigma Plot 1 1 .0 software. [*: p<0.05; **: p<0.01 ; ***: p<0.001 ].
Figure 9: Fluvastatin also synergizes with Tizoxanide, a metabolite of NTZ, to reduce fibrosis in TGFB-induced hHSC.
Serum-deprived HSC were preincubated for 1 hour with suboptimal doses of Tizoxanide (TZ), Fluvastatin, or a combination of both products. Data are presented as mean of quadruplicates. Statistical analyses were performed by one-way ANOVA followed by Bonferroni post-hoc tests, using Sigma Plot 1 1.0 software. [*: p<0.05; **: p<0.01 ; ***: p<0.001 (comparison versus 'product combination' group)].
Figure 10 Combination of NTZ with Simvastatin svnergisticallv prevents CCI4-induced levels of circulating TBA concentration.
250-275g rats were intraperitoneal^ injected with olive oil (ctrl group) or with CCI4 emulsified in olive oil (CCI4: olive oil 1 :2 v/v, final CCI4 concentration : 2ml/kg) twice weekly for 3 weeks. Concomitantly, the olive oil injected group was placed on control diet while the CCI4 injected groups were placed on control diet or diet supplemented with NTZ 30 mg/kg/day, SIMVA 10 mg/kg/day or a combination NTZ 30 mg/kg/day/SIMVA 10 mg/kg/day. After the sacrifice, circulating TBA concentration was determined. Data are presented as mean ± standard deviation (SD) Statistical analyses were performed using Sigma Plot 1 1 .0 software: Olive Oil vs CCI4 : Mann-Whitney Rank Sum Test: ###: p<0.001 ; CCI4 vs CCI4+ cpd treatment:
Kruskal Wallis test, followed by Dunn's post ***: p<0.001 ; NTZ/SIMVA combination vs NTZ 30 mpk or SIMVAI 10 mpk: Mann-Whitney Rank Sum Test:: $$$ p<0.001.
DETAILED DESCRIPTION OF THE INVENTION
In the experimental part of the present application, it is shown that a combination of (i)
NTZ, or TZ, with (ii) a statin may synergistically confer antifibrotic properties in activated myofibroblasts. Moreover, it is shown that combinations of (i) NTZ or TZ, with (ii) a statin can also reduce altered levels of total biliary acids in a model of liver injury. Accordingly, the present invention relates to a novel synergistic combination of active agents, comprising (i) NTZ or a derivative of NTZ such as a deuterated derivative of NTZ (NTZ-D), TZ or TZG, or a pharmaceutically acceptable salt of NTZ, NTZ-D, TZ or of TZG, and (ii) a statin.
In particular, the present invention relates to the synergistic combination of (i) NTZ, a deuterated derivative of NTZ, or TZ, or a pharmaceutically acceptable salt of NTZ, of TZ, or of a deuterated derivative of NTZ, and (ii) a statin, for use in a method for the treatment of a cholestatic or fibrotic disorder.
Furthermore, the invention relates to the use of the synergistic combination of the invention, comprising (i) NTZ, NTZ-D, TZ or of TZG, or a pharmaceutically acceptable salt of NTZ, NTZ-D, TZ or of TZG, and (ii) a statin, for the manufacture of a medicament useful for the treatment of a cholestatic and fibrotic disorder. The invention also relates to a pharmaceutical composition comprising (i) NTZ, NTZ-D, TZ or of TZG, or a pharmaceutically acceptable salt of NTZ, NTZ-D, TZ or TZG, and (ii) a statin, said components (i) and (ii) acting synergistically as described herein. The pharmaceutical composition according to the invention is useful for treating a cholestatic or fibrotic disorder.
Although the causative agents or initiating events of fibrotic disorders are quite diverse and their pathogenesis is variable, a common feature in affected tissues is the presence of large numbers of activated fibroblasts called myofibroblasts ((Rosenbloom, Mendoza et al., 2013)). Fibrotic stimulus such as TGF 1 can induce differentiation of fibroblasts to myofibroblasts (Leask and Abraham, 2004; Leask, 2007). Myofibroblasts are metabolically and morphologically distinctive fibroblasts whose activation play a key role during the fibrotic response. Furthermore, these myofibroblasts display unique biological functions including expression of proteins involved in extracellular matrix formation such as different forms of collagen. The induction of osmooth muscle actin (a-SMA) expression is a recognized hallmark of quiescent fibroblast to activated myofibroblast differentiation and can be used as a physiological read-out to evaluate the potency of the drugs that interfere with the fibrotic process. Tumor Growth β factors, and especially the Tumor Growth Factor beta 1 (TGF31 ) are recognized physiological signals that induce the phenotypic transformation of fibroblasts
into profibrotic myofibroblasts that express high levels of a-SMA and high levels of extracellular matrix proteins, which are then secreted and form the fibrotic scar tissue.
Moreover, it is known that the proliferation and the activation of fibroblasts is responsible for the production of several connective tissue components (for example, collagens, elastin, proteoglycans, and hyaluronan) that constitute the extracellular matrix (Kendall and Feghali-Bostwick, 2014).
Unexpectedly, NTZ but also its active metabolite TZ and NTZ deuterated derivatives reveal antifibrotic properties since these compounds dose-dependently reduced the level of a-SMA in TGF -induced hepatic stellate cells and in primary fibroblasts from other organs. Moreover, NTZ and its metabolite TZ revealed anticholestatic properties by their ability to reduce circulating total bile acids in a model of liver injury.
NTZ, TZ and TZG to be used according to the invention have the following Formula (I), (II) and (III) respectively:
NTZ and TZ(G) ("TZ(G)" referring to "TZ or TZG")) were known for their antiparasitic and antiviral activities, but the prior art does not teach NTZ, and TZ(G) have anticholestatic and anti-fibrotic effect.
The inventors have demonstrated in a new and inventive way that these compounds have a therapeutic effect in the treatment of cholestasis or fibrosis.
The prior art does neither teach that deuterated derivatives of NTZ (also referred to elsewhere in this application as "NTZ-D") have anticholestatic or anti-fibrotic effects.
According to the present invention, deuterated derivatives of NTZ to be used in the composition according to the invention have the following Formula (IV):
R2c, identical or different, represent a hydrogen atom or a deuterium atom, with the proviso that R2a, R2b, R2c are not simultaneously a hydrogen atom.
In a particular embodiment, R2a, R2b and R2c represent a deuterium atom.
In a particular embodiment, R2a and R2b represent a deuterium atom, R2c represents a hydrogen atom.
In a particular embodiment, R2a represents a deuterium atom, R2b and R2c represent a deuterium atom.
Examples of such compounds of the invention include :
Cpd.1 : 2-[(5-nitro-1 ,3-thiazol-2-yl)carbamoyl]phenyl (d3)ethanoate;
Cpd.2 : 2-[(5-nitro-1 ,3-thiazol-2-yl)carbamoyl]phenyl (d2) ethanoate; and
Cpd.3 : 2-[(5-nitro-1 ,3-thiazol-2-yl)carbamoyl]phenyl (d1 ) ethanoate;
In the context of the present invention, "NTZ, NTZ-D and TZ(G), and pharmaceutically acceptable salts of NTZ, NTZ-D and TZ(G)" or "compound of formula (I), (II), (III) and (IV),
and pharmaceutically acceptable salts of compound of formula (I), (II), (III) and (IV)" are collectively referred to as "component (i)" or "component (i) of the combination".
In the context of the present invention, "component (ii)" or "component (ii) of the combination" refers to "at least one statin" or "a statin".
The inventors have also demonstrated in a new and inventive way that the combination of NTZ, NTZ-D, TZ(G) with a statin may have a synergistic anticholestatic and/or anti-fibrotic effect in human HSCs.
In the present invention, synergism is defined by a coordinated or correlated action of two or more structures so that the combined action is greater than the sum of each acting separately.
Accordingly, the invention relates to the synergistic combination of (i) NTZ, NTZ-D, TZG, or a pharmaceutically acceptable salt of NTZ, NTZ-D or TZ(G), with (ii) a statin. The invention further relates to this combination, for use in a method for the treatment of a cholestatic or fibrotic disorder.
According to a particular embodiment of the invention, the combination comprises (i)
NTZ, NTZ-D or TZ, or a pharmaceutically acceptable salt of NTZE, NTZ-D or TZ, and (ii) a statin.
In a further aspect, the invention relates to the synergistic combination of the invention, for use in the inhibition of proliferation and/or activation of fibroblasts. As is known in the art, fibroblasts are responsible for the production of collagen fibers or other connective tissue components of the extracellular matrix.
According to the present invention, the terms "fibrosis", "fibrotic disease", "fibrotic disorder" and declinations thereof denote a pathological condition of excessive deposition of fibrous connective tissue in an organ or tissue. More specifically, fibrosis is a pathological process, which includes a persistent fibrotic scar formation and overproduction of extracellular matrix, by the connective tissue, as a response to tissue damage. Physiologically, the deposit of connective tissue can obliterate the architecture and function of the underlying organ or tissue.
According to the present invention, the fibrosis or fibrotic disorder may be associated with any organ or tissue fibrosis. Illustrative, non-limiting examples of particular organ fibrosis include liver, gut, kidney, skin, epidermis, endodermis, muscle, tendon, cartilage, heart, pancreas, lung, uterus, nervous system, testis, penis, ovary, adrenal gland, artery, vein, colon, intestine (e.g. small intestine), biliary tract, soft tissue (e.g. mediastinum or retroperitoneum), bone marrow, joint, eye or stomach fibrosis, in particular liver, kidney, skin, epidermis, endodermis, muscle, tendon, cartilage, heart, pancreas, lung, uterus, nervous system, testis, ovary, adrenal gland, artery, vein, colon, intestine (e.g. small intestine), biliary
tract, soft tissue (e.g. mediastinum or retroperitoneum), bone marrow, joint or stomach fibrosis.
According to the present invention, the terms "cholestasis" or "cholestatic disease", or "cholestatic disorder" and declinations thereof denote a pathological condition defined by a decrease in bile flow due to impaired secretion by hepatocytes or to obstruction of bile flow through intra-or extrahepatic bile ducts. Therefore, the clinical definition of cholestasis is any condition in which substances normally excreted into bile are retained.
In a particular embodiment, the fibrotic disorder is selected in the group consisting of a liver, gut, lung, heart, kidney, muscle, skin, soft tissue (e.g. mediastinum or retroperitoneum), bone marrow, intestinal, and joint (e.g. knee, shoulder or other joints) fibrosis.
In a preferred embodiment, the fibrotic disorder is selected in the group consisting of the liver, lung, skin, kidney and intestinal fibrosis.
In a more preferred embodiment of the present invention, treated fibrotic disorder is selected in the group consisting of the following non exhaustive list of fibrotic disorders: non- alcoholic steatohepatitis (NASH), pulmonary fibrosis, idiopathic pulmonary fibrosis, skin fibrosis, eye fibrosis, endomyocardial fibrosis, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis (a complication of coal workers' pneumoconiosis), proliferative fibrosis, neoplastic fibrosis, lung fibrosis consecutive to chronic inflammatory airway disease (COPD, asthma, emphysema, smoker's lung, tuberculosis), alcohol or drug-induced liver fibrosis, liver cirrhosis, infection-induced liver fibrosis, radiation or chemotherapeutic-induced fibrosis, nephrogenic systemic fibrosis, Crohn's disease, ulcerative colitis, keloid, old myocardial infarction, scleroderma/systemic sclerosis, arthrofibrosis, some forms of adhesive capsulitis, chronic fibrosing cholangiopathies such as Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis (PBC), biliary atresia, familial intrahepatic cholestasis type 3 (PFIC3), peri- implantational fibrosis and asbestosis.
According to a particular embodiment of the invention, the cholestestatic disease is selected in the group consisting of primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), Intrahepatic Cholestasis of Pregnancy, Progressive Familial Intrahepatic Cholestasis, Biliary atresia, Cholelithiasis, Infectious Cholangitis, Cholangitis associated with Langerhans cell histiocytosis, Alagille syndrome, Nonsyndromic ductal paucity, Drug-induced cholestasis, and Total parenteral nutrition-associated cholestasis. In a preferred embodiment, the cholestatic disease is PBC or PSC, in particular PBC.
The term "treatment" or "treating" refers to the curative or preventive of a cholestatic or fibrotic disorder in a subject in need thereof. The treatment involves the administration of the combination of the invention to a subject having a declared disorder, i.e. to a patient, to cure,
delay, reverse, or slow down the progression of the disorder, improving thereby the condition of the subject. A treatment may also be administered to a subject that is healthy or at risk of developing a cholestatic or fibrotic disorder to prevent or delay the disorder.
Therefore, according to the invention, the treatment of a fibrotic disorder involves the administration of the combination of the present invention, for example in the form of a pharmaceutical composition containing components (i) and (ii) of the combination, to a subject having a declared disorder to cure, delay, reverse or slow down the progression of the disorder, thus improving the condition of the patient or to a healthy subject, in particular a subject who is at risk of developing a cholestatic or fibrotic disorder.
The subject to be treated is a mammal, preferably a human. The subject to be treated according to the invention can be selected on the basis of several criteria associated with cholestatic or fibrotic diseases such as previous drug treatments, associated pathologies, genotype, exposure to risk factors, viral infection, as well as on the basis of the detection of any relevant biomarker that can be evaluated by means of imaging methods and immunological, biochemical, enzymatic, chemical, or nucleic acid detection methods.
According to the present invention, the term "statin(s)" refers the HMG-CoA reductase inhibitors, which are a class of cholesterol lowering drugs that inhibit the enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol. Elevated blood cholesterol levels have been associated with cardiovascular disease (CVD), and many studies have shown that the risk of CVD events can be reduced by lipid-lowering therapy. At the beginning, the lipid-lowering armamentarium was limited essentially to a low saturated fat and cholesterol diet, bile acid sequestrants (cholestyramine and colestipol), nicotinic acid (niacin), fibrates and probucol. Unfortunately, all of these treatments have limited efficacy or tolerability, or both.
The HMG-CoA reductase inhibitors described above belong to a structural class of compounds which contain a moiety which can exist as either a 3-hydroxy lactone ring or as the corresponding ring opened dihydroxy open-acid. Salts of the dihydroxy open-acid can be prepared, and in fact, as noted above, several of the marketed statins are administered as the dihydroxy open acid salt forms.
For example, lovastatin and simvastatin are marketed worldwide in their lactonized form.
Statins have been found to reduce cardiovascular disease and mortality in those who are at high risk. The evidence is strong that statins are effective for treating CVD in the early stages of a disease (secondary prevention) and in those at elevated risk but without CVD (primary prevention).
According to the invention, the term "statin(s)" as used herein includes, but is not limited to fluvastatin, atorvastatin, mevastatin, cerivastatin, lovastatin, simvastatin, rosuvastatin, pravastatin, and pitavastatin. According to a particular embodiment of the invention, the statin is selected from pitavastatin, fluvastatin, simvastatin and atorvastatin.
Statins may be in the form of a salt, hydrate, solvate, polymorph, or a co-crystal.
Statins may also be in the form of a hydrate, solvate, polymorph, or a co-crystal of a salt. Statins may also be present in the free acid of lactone form according to the present invention.
Component (ii) of the combination may comprise one or more statin, i.e. one statin or a mixture of statins.
According to the invention the statin comprised in the combination of the invention is selected so that the combination of said statin and component (i) of the combination of the invention provides a synergistic action against cholestasis or fibrosis. Such synergy may be determined according to methods well-known in the art, such as by using the Excess Over Bliss (EOB) method described in the examples.
In a preferred embodiment, the statin in the synergistic combination of the present invention is selected in the group consisting of lovastatin, rosuvastatin, pravastatin, pitavastatin, fluvastatin, simvastatin and atorvastatin, in particular in the group consisting of pitavastatin, fluvastatin and simvastatin.
Another aspect of the invention relates to the synergistic combination described above in the form of a pharmaceutical composition. Therefore, the invention also relates to a pharmaceutical composition comprising (i) NTZ, NTZ-D or TZ(G), or a pharmaceutically acceptable salt of NTZ, NTZ-D or TZ(G), and (ii) a statin.
In yet another aspect, the present invention relates to the synergistic combination described above, in the form of a kit-of-parts for the simultaneous, sequential or separate administration of its components, as described in more details below.
The invention provides also a method of treatment of cholestasis or fibrosis.
The treatment involves the administration of the synergistic combination of the invention to a patient having a declared disorder to cure, delay, or slow down the progress, thus improving the condition of the patient or to a healthy subject, in particular a subject who is at risk of developing a cholestatic or fibrotic disease, to prevent the disease.
The subjects to be treated according to the invention can be selected on the basis of several criteria associated to fibrotic diseases such as previous drug treatments, associated pathologies, genotype, exposure to risk factors, viral infection, as well as any other relevant biomarker that can be evaluated by means of imaging methods and immunological, biochemical, enzymatic, chemical, or nucleic acid detection method.
Synthesis of NTZ or TZ can be for example carried out as described in (Rossignol and Cavier, 1975), or by any other way of synthesis known by a person skilled in the art. TZG can be, for example, synthesized according to way of synthesis known in the art such as in Wadouachi 201 1. S'agit-il de A Wadouachi, J Kovensky, Synthesis of Glycosides of Glucuronic, Galacturonic and Mannuronic Acids: An Overview, Molecules, 201 1 , 16(5), 3933- 3968.
In a particular embodiment, the treatment of a cholestatic or fibrotic disorder may comprise the administration of a composition comprising at least two compounds selected from NTZ, NTZ-D and TZ(G). In this embodiment, the administered statin is provided in the same composition as the two compounds, or in a separate form, such as in a different composition.
In another embodiment, the synergistic combination of the invention is for simultaneous, sequential or separate administration in therapy, therefore being possibly included in different compositions. In case of sequential administration, component (i) of the combination may be administrated prior to component (ii), or component (ii) is administrated prior to component (i). As such, the invention also relates to kit-of-parts comprising the synergistic combination of (i) NTZ, NTZ-D and TZ(G), or a phamaceutically acceptable salt of NTZ, NTZ-D and TZ(G), ; and (ii) a statin, , for simultaneous, sequential or separate administration.
NTZ, NTZ-D, TZ(G) and a statin can be formulated as pharmaceutically acceptable salts, particularly acid or base salts compatible with pharmaceutical use. Salts of NTZ, NTZ- D, TZ(G) and a statin include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable base addition salts, pharmaceutically acceptable metal salts, ammonium and alkylated ammonium salts. These salts can be obtained during the final purification step of the compound or by incorporating the salt into the previously purified compound.
Combination of a components (i) and (ii), in particular of a compound of Formula (I), (II), (III) or (IV) with one or more statin(s) can be formulated as pharmaceutically acceptable nontoxic salts obtained from organic or inorganic bases or acids of compound of Formula (I), (II), (III) (IV) or statin(s). These salts can be obtained during the final purification step of the compound or by incorporating the salt into the previously purified compound.
The pharmaceutical compositions of the present invention comprising component (i) and/or (ii), in particular comprising a compound of Formula (I), (II), (III) and/or one or more statin(s) can also comprise one or several excipients or vehicles, acceptable within a pharmaceutical context (e.g. saline solutions, physiological solutions, isotonic solutions, etc., compatible with pharmaceutical usage and well-known by one of ordinary skill in the art).
These compositions can also comprise one or several agents or vehicles chosen among dispersants, solubilisers, stabilisers, preservatives, etc. Agents or vehicles useful for these formulations (liquid and/or injectable and/or solid) are particularly methylcellulose, hydroxymethylcellulose, carboxymethylcellulose, polysorbate 80, mannitol, gelatin, lactose, vegetable oils, acacia, liposomes, etc.
These compositions can be formulated in the form of injectable suspensions, gels, oils, ointments, pills, tablets, suppositories, powders, gel caps, capsules, aerosols, etc., eventually by means of galenic forms or devices assuring a prolonged and/or slow release. For this kind of formulation, agents such as cellulose, carbonates or starches can be advantageously used.
The pharmaceutical compositions of the present invention comprising component (i) and/or (ii) of the combination, such as a compound of Formula (I), (II), (III) and/or one or more statin(s) (the statin being selected, as mentioned above, among those that allows a synergistic effect with component (i) of the combination of the present invention) may be administered by different routes and in different forms. For example, the compound(s) may be administered via a systemic way, per os, parenterally, by inhalation, by nasal spray, by nasal instillation, or by injection, such as for example intravenously, by intra-muscular route, by subcutaneous route, by transdermal route, by topical route, by intra-arterial route, etc.
Of course, the route of administration will be adapted to the form of component (i) in combination with one or more statin(s) according to procedures well known by those skilled in the art.
In a particular embodiment, the component(s) (i) and (ii) are formulated as a tablet or as tables. In another particular embodiment, the compounds are administered orally.
NTZ, NTZ-D or TZ(G) in combination with one or more statin(s) is administered in a therapeutically effective amount. Within the context of the invention, the term "effective amount" refers to an amount of the compound sufficient to produce the desired therapeutic result.
The frequency and/or dose relative to the administration can be adapted by one of ordinary skill in the art, in function of the patient, the pathology, the form of administration, etc. Typically, the combination (such as in the form of a pharmaceutical composition or a kit- of-parts) of the present invention can be administered for the treatment of a cholestatic or fibrotic disease at a dose for component (i) of the combination comprised between 0.01 mg/day to 4000 mg/day, such as from 50 mg/day to 2000 mg/day, such as from 100 mg/day to 2000 mg/day; and particularly from 100 mg/day to 1000 mg/day. In a particular embodiment, the NTZ, TZ(G), or a pharmaceutically acceptable salt thereof, is administered at a dose of about 1000 mg/day (i.e at a dose of 900 to 1 100 mg/day), in particular at 1000
mg/day. In a particular embodiment, NTZ, TZ(G), or a pharmaceutically acceptable salt thereof, is administered orally at a dose of about 1000 mg/day, in particular at 1000 mg/day, in particular as a tablet. Administration can be performed daily or even several times per day, if necessary. In one embodiment, the compound is administered at least once a day, such as once a day, twice a day, or three times a day. In a particular embodiment, the compound is administered once or twice a day. In particular, oral administration may be performed once a day, during a meal, for example during breakfast, lunch or dinner, by taking a tablet comprising the compound at a dose of about 1000 mg, in particular at a dose of 1000 mg. In another embodiment, a tablet is orally administered twice a day, such as by administering a first tablet comprising the compound at a dose of about 500 mg (i.e. at a dose of 450 to 550 mg), in particular at a dose of 500 mg, during one meal, and administering a second tablet comprising the compound at a dose of about 500 mg, in particular at a dose of 500 mg, during another meal the same day.
The dose of the statin in the said combination may vary according to the statin itself. The dose is adapted to the efficiency of the statin according to typical statin regimen.
For example, for Fluvastatin, the dose may be comprised between 10 to 50 mg/day, and particularly from 20 to 40 mg/day.
For pitavastatin the dose may be comprised between 0,1 mg/day to 6 mg/day, and particularly from 1 to 4 mg/day.
For both Simvastatin and Atorvastatin, the dose may be comprised between 1 mg/day to 100 mg/day, and particularly from 10 to 80 mg/day.
In a preferred embodiment of the invention, component (i), in particular NTZ, is used in combination with fluvastatin at a dose comprised between 100 mg/day to 1000 mg/day for NTZ and 1 to 4 mg/day for fluvastatin.
In another preferred embodiment of the invention, component (i), in particular NTZ, is used in combination with pitavastatin at a dose comprised between 100 mg/day to 1000 mg/day for NTZ and 1 to 4 mg/day for pitavastatin.
In another preferred embodiment of the invention, component (i), in particular NTZ, is used in combination with Simvastatin or Atorvastatin at a dose comprised between 100 mg/day to 1000 mg/day for NTZ and 10 to 80 mg/day for Simvastatin and Atorvastatin.
In another preferred embodiment, the active ingredients are administered as one or more pharmaceutical composition(s) in the form of a pill or tablet intended for an oral ingestion.
Administration can be performed daily or even several times per day, if necessary. Suitably, the course of treatment with the combination of the invention is for at least 1 week, in particular for at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 or 24 weeks or more. In
particular, the course of treatment with NTZ, TZ(G) or a pharmaceutically acceptable salt thereof is for at least 1 year, 2 years, 3 years, 4 years or at least 5 years.
In a particular embodiment, the invention relates to the treatment of a cholestatic or fibrotic disease, in particular liver fibrosis, more particularly liver fibrosis consecutive to NASH, in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of the combination of the invention, including in particular administering NTZ at a dose of 1000 mg/day, in particular by administering a tablet containing 500 mg of NTZ twice a day, in particular during two different meals. In a particular embodiment, the invention relates to a combination of the present invention, further combined to at least one other therapeutically active agent, such as other molecules with known antifibrotic activity. This further combination of the present invention is useful for the treatment of a cholestatic or fibrotic disorder.
According to a variant of this embodiment, NTZ, TZ or a deuterated derivative of NTZ in combination with one or more statin(s) can be combined with any antifibrotic compound such as pirfenidone or receptor tyrosine kinase inhibitors (RTKIs) such as Nintedanib, sorafenib and other RTKIs, or angiotensin II (AT1 ) receptor blockers, or CTGF inhibitor, or any antifibrotic compound susceptible to interfere with the TGFp- and BMP-activated pathways including activators of the latent TGFp complex such as MMP2, MMP9, THBS1 or cell-surface integrins, TGF3 receptors type I (TGFBRI) or type II (TGFBRII) and their ligands such as TGF3, Activin, inhibin, Nodal, anti-Mijllerian hormone, GDFs or BMPs, auxiliary co- receptors (also known as type III receptors), or components of the SMAD-dependent canonical pathway including regulatory or inhibitory SMAD proteins, or members of the SMAD-independent or non-canonical pathways including various branches of MAPK signaling, TAK1 , Rho-like GTPase signaling pathways, phosphatidylinositol-3 kinase/AKT pathways, TGFp-induced EMT process or canonical and non-canonical Hedgehog signaling pathways including Hh ligands or target genes, or any members of the WNT, or Notch pathways which are susceptible to influence TGFp signaling.
Thus, the invention also relates to a pharmaceutical composition, in particular for its use in a method for the treatment of a cholestatic or fibrotic disease, comprising a compound selected from component (i) with component (ii), in combination with at least one therapeutically active agent with known antifibrotic activity selected from pirfenidone or receptor tyrosine kinase inhibitors (RTKIs) such as Nintedanib, sorafenib and other RTKIs, or angiotensin II (AT1 ) receptor blockers, or CTGF inhibitor, or antifibrotic compound susceptible to interfere with the TGF3- and BMP-activated pathways including activators of the latent TGF3 complex such as MMP2, MMP9, THBS1 or cell-surface integrins, TGF3
receptors type I (TGFBRI) or type II (TGFBRII) and their ligands such as TGF3, Activin, inhibin, Nodal, anti-Mijllerian hormone, GDFs or BMPs, auxiliary co-receptors (also known as type III receptors), or components of the SMAD-dependent canonical pathway including regulatory or inhibitory SMAD proteins, or members of the SMAD-independent or non- canonical pathways including various branches of MAPK signaling, TAK1 , Rho-like GTPase signaling pathways, phosphatidylinositol-3 kinase/AKT pathways, TGF3-induced EMT process, or canoninal and non-canonical Hedgehog signaling pathways including Hh ligands or target genes, or any members of the WNT, or Notch pathways which are susceptible to influence TGF3 signaling, for use in a method for treating a cholestatic or fibrotic disorder.
In another particular embodiment, other classes of molecules that could also be combined with component (i) and component (ii) include JAK/STAT inhibitors, or other antiinflammatory and/or immunosuppressant agents. The non exhaustive list of these agents includes but is not limited to glucocorticoids, NSAIDS, cyclophosphamide, nitrosoureas, folic acid analogs, purine analogs, pyrimidine analogs, methotrexate, azathioprine, mercaptopurine, ciclosporin, myriocin, tacrolimus, sirolimus, mycophenolic acid derivatives, fingolimod and other sphingosine-1 -phosphate receptor modulators, monoclonal and/or polyclonal antibodies against such targets as proinflammatory cytokines and proinflammatory cytokine receptors, T-cell receptor, integrins. Other classes of molecules that could also be combined with component (i) and component (ii), include molecules that could potentially enhance the exposure or the effect of component (i) with component (ii).
In another embodiment, components (i) and (ii), are administered as the sole active ingredient.
In a further embodiment, the present invention provides methods of treating a cholestatic or fibrotic disease comprising the administration of the combination of the present invention, in particular in the form of a pharmaceutical composition or of a kit-of-parts containing component (i) and component (ii).
The invention is further described with reference to the following, non-limiting, examples.
EXAMPLES
MATERIALS AND METHODS
Compounds were dissolved in dimethyl sulfoxide (DMSO, Fluka cat# 41640). Nitazoxanide (INTERCHIM cat#RQ550U), tizoxanide (INTERCHIM cat#RP253) were obtained
commercially, as well as Pitavastatin (INTERCHIM cat#15414), Simvastatin (Sigma Aldrich cat #S6196), Fluvastatin (Sigma Aldrich cat#Y0001090), Pravastatin (Selleckchem cat #S3036), Rosuvastatin (Selleckchem cat#S2169), Lovastatin (Selleckchem cat#S4223), Atorvastatin (Sigma Aldrich cat#PZ0001 ). hHSC culture
The human primary hepatic stellate cells (hHSC) (Innoprot) were cultured in STeCM medium (ScienCell cat# 5301 ) that was supplemented with 2% fetal bovine serum (FBS, ScienCell cat# 0010), 1 % penicillin/streptomycin (ScienCell cat# 0503) and stellate cell growth supplement (SteCGS; ScienCell cat# 5352). Cell-culture flasks were coated with Poly-L Lysine (Sigma cat# P4707) for a better adherence.
Preparation of compositions
2 components combination matrix (NTZ/statin or TZ/statin)
The checkerboard matrix was adopted. NTZ or TZ and statin stocks were serially diluted in DMSO in a 5-points series in a row (statin) and a column (NTZ or TZ) of a 96-well plate. A 6th point was filled with 100% DMSO without compound. Subsequently, the 6X6 combination matrix was generated by 1 :1 mixing of all single agent concentrations. The five test concentrations for each compound were chosen based on the respective IC50 of each compound as single agent obtained by measuring a-SMA content in the HSC model stimulated with TGF-βΙ . Then, 2-fold and 4-fold higher and lower concentrations were selected.
For Pravastatin and Rosuvastatin which were found inactive and weak inhibitor, respectively in TGF-βΙ stimulated HSC model, the dose range was selected arbitrarily (5 doses serially diluted 2 fold starting from 4μΜ).
Activation of hHSC with TGF-βΙ and compound treatment
The human primary hepatic stellate cells (hHSC) (Innoprot) were cultured under standard conditions, as described above. The cells were subsequently plated at a density of 2 x 104cells/well into 96-well plates for the measure of a-SMA by ELISA. The next day, cell culture medium was removed, and cells were washed with PBS (Invitrogen cat# 14190). hHSC were deprived for 24 hours in serum-free and SteCGS-free medium. For the treatments with NTZ, statins (Pitavastatin, Fluvastatin, Simvastatin, Atorvastatin, Lovastatin, Rosuvastatin, Pravastatin) and the respective NTZ/statin combinations and also for the treatment with TZ, statins (Pitavastatin, Simvastatin, Fluvastatin, Pravasatin) and the respective combinations TZ/statin, the serum-deprived hHSC were preincubated for 1 hour
with the compounds followed by the addition of the profibrogenic stimuli TGF-βΙ (PeproTech cat# 100-21 , 1 ng/mL) in serum-free and SteCGS-free medium for an additional 48 hour period.
At the end of treatment, cells were washed with PBS (Invitrogen, cat# 14190) before the addition of 50 μΙ of lysis buffer (CelLyticT MT reagent; Sigma #C3228). Plates were then incubated for 30 min on ice using a plate shaker, before storage at -20 C.
a-SMA ELISA
The level of a-SMA was measured using a Sandwich ELISA. Briefly, the wells of an ELISA plate were first coated with the capture antibody (mouse monoclonal anti-ACTA2, Abnova) at 4°C overnight. After 3 washes in PBS + 0,2% Tween 20, a blocking solution consisting of PBS +0.2% BSA was added for one hour followed by another washing cycle. The cell lysates were transferred into the wells for binding to the capture antibody for a period of 2h at room temperature. After the washing procedure, the detection antibody (biotinylated mouse monoclonal anti-ACTA2, Abnova) was added for 2 hours at room temperature followed by 3 washes. For the detection, an HRP-conjugated Streptavidin (R&D Systems cat# DY998) was first applied for 30 min at room temperature. After washing, the HRP substrate TMB (;BD,#555214) was added and incubated for 7min at room temperature in the dark. Upon oxidation, TMB forms a water-soluble blue reaction product that becomes yellow with addition of sulfuric acid (solution stop), enabling accurate measurement of the intensity at 450nm using a spectrophotometer. The developed color is directly proportional to the amount of a-SMA present in the lysate.
Determination of synergism by Excess Over Bliss (EOB) method
The values obtained in the aSMA ELISA assays were first transformed into percentage inhibitions over TGF-βΙ control. Then, using these percentage inhibitions converted into fractions (percentage divided by 100), EOB (Excess Over Bliss) was determined to define the synergistic effects of drug combinations. Expected Bliss additivism score (E) was firstly determined by the equation:
E = (A + B) - (A x B) where A and B are the percentage inhibitions converted into fractions within a range of 0 to 1 of NTZ (A) and a given statin (B) at a given dose. The difference between the Bliss expectation and the observed inhibition of the combined NTZ/statin at the same dose is the 'Excess over Bliss' score.
Excess over Bliss score = 0 indicates that the combination treatment is additive (as expected for independent pathway effects);
Excess over Bliss score >0 indicates activity greater than additive (synergy); and
Excess over Bliss score <0 indicates the combination is less than additive (antagonism). For each product combination (NTZ + statin), an additional total Bliss score was calculated by summation of all EOB.
To validate the synergism, the experimental values corresponding to top EOB score for each NTZ/statin combination were plotted in a bar graph. The significance of the observed differences between NTZ/statin or TZ/statin and single agents were estimated by a student t- test or Mann-Whitney Rank Sum Test using Sigma Plot 1 1 .0 software. [*: p<0.05; **: p<0.01 ; ***: p<0.001 ].
Evaluation of the synergistic therapeutic effect of NTZ /SIMVA combination in CCI4- induced liver fibrosis
The synergistic therapeutic effect of NTZ /SIMVA combination was assessed in a rat model of CCI4-induced liver injury.
OFA S;Dawley rats (initial body weight 250-275g) were randomized according to their body weight into 5 groups and treated for 3 weeks. The rats were intraperitoneally injected with olive oil (ctrl group) or with CCI4 emulsified in olive oil (CCI4: olive oil 1 :2 v/v, final CCI4 concentration: 2ml/kg) twice weekly. Concomitantly, the olive oil injected group was placed on control diet while the CCI4 injected groups were placed on control diet or diet supplemented with compounds. 3 regimen were prepared corresponding respectively to an exposure of NTZ 30 mg/kg/day, SIMVA 10 mg/kg/day or NTZ /SIMVA 30/10 mg/kg/day. The last day of treatment, the rats were sacrificed after a 6h fasting period. Blood samples were collected and the serum was isolated for biochemical analyses. Evaluation of the synergistic therapeutic effect of NTZ /SIMVA combination in a DDC- induced cholestasis model:
The synergistic therapeutic effect of NTZ /SIMVA combination will be assessed in a DDC- induced cholestasis model
C57BL/6 mice will be fed for 8 weeks a 0,1 % DDC-supplemented diet, or 0.1 % DDC- supplemented diet corresponding respectively to an exposure of NTZ 100 mg/kg/day, or SIMVA 10 mg/kg/day or a standard mouse diet (Ssniff), The last day of treatment, the mice will be sacrificed after a 6h fasting period. Blood samples will be taken for biochemical analyses and liver will be rapidly excised for biochemical and histological studies.
Evaluation of the synergistic therapeutic effect of NTZ /SIMVA combination in a chronic CCI4- induced liver fibrosis model
9 week-old C57BL/6 mice will be placed on control diet or diet supplemented with NTZ for 6 weeks. 8 diet regimen containing NTZ and/or SIMVA will be prepared corresponding respectively to an exposure of NTZ at 30 or100 mg/kg/day or SIMVA at 3 or10 mg/kg/day or a combination of NTZ/SIMVA 30/3; 100/3; 30/10,100/10 mg/kg/day, respectively... Concomitantly, and for the total duration of 6 weeks, the mice will be treated 3 times a week with CCI4 dissolved in olive oil or vehicle by oral gavage. The amount of CCI4 will be progressively increased from 0.875 ml/kg to 2.5ml/kg.The last day of treatment, the mice will be sacrificed after a 6h fasting period.. Blood samples will be collected and the serum will be isolated for biochemical analyses. The liver will be rapidly excised for biochemical, histological & expression studies.
Evaluation of the synergistic therapeutic effect of NTZ /SIMVA combination in a BDL model
Surgical bile duct ligation will be performed on rats in order to induce an extrahepatic cholestasis and subsequently liver fibrosis. After a short recovery period, animals will be treated with NTZ at 30 or 100 mg/kg/day, SIMVA at 3 or 10 mpk, or combinations of NTZ/SIMVA 30/3, or 100/10 mg/kg/day for one or two weeks. The last day of treatment, the mice will be sacrificed after a 6h fasting period. Blood samples will be collected and the serum will be isolated for biochemical analyses. The liver will be rapidly excised for biochemical, histological & expression studies.
Measurement of plasmatic concentration of Total Bile Acids
The plasmatic concentration of Total Bile Acids (TBA) was determined using the appropriate Randox kit for the Daytona automated Analyzer (Randox, cat#BI 3863). In the presence of Thio-NAD, the enzyme 3-a hydroxysteroid dehydrogenase (3-a HSD) converts bile acids to 3-keto steroids and Thio-NADH. The reaction is reversible and 3-a HSD can convert 3- ketosteroids and Thio-NADFH-to bile acids and Thio- NAD. In the presence of excess NADH, the enzyme cycling occurs efficiently and the rate of formation of Thio-NADH is determined by measuring specific change of absorbance at 405nm. Results are expressed in μη"ΐοΙ/Ι_.
Results and conclusions:
The abnormal persistence of differentiated myofibroblasts is a characteristic of many fibrotic diseases. Following liver injury, quiescent HSCs undergo a process of activation that is characterized by a differentiation into (a-SMA)-positive myofibroblasts. In an attempt to find new antifibrotic molecules, a library of FDA-approved drugs was phenotypically screened in a model of human HSC activated with the profibrogenic cytokine TGF-βΙ . The level of a-SMA, a hallmark of fibrotic lesions, was used to evaluate the potency of the drugs to interfere with the fibrotic process. The screening campaign led to the identification of nitazoxanide (NTZ), which dose-dependently reduced the level of a-SMA in TGF3-induced HSCs. Overall, NTZ exhibited an I C50 comprised between 0.1 and 3μΜ (Fig. 1A).
Since it is known that NTZ is rapidly hydrolyzed into its active metabolite tizoxanide (TZ) (Broekhuysen, Stockis et al., 2000), this metabolite was also evaluated for its antifibrotic activity in HSC. TZ showed a profile similar to the parent drug with an IC50 comprised between 0.1 and 3 μΜ (Fig. 1 B). Interestingly, specific statins but not all were also identified during the screening campaign. The dose-response analyses performed in the TGFp - induced HSC model (Fig. 2) reveal that the 7 tested statins are not equivalent regarding their antifibrotic properties.
Typically, Pitavastatin (Fig. 2A) and Fluvastatin (Fig. 2B), the most potent antifibrotic statins, exhibited an IC50 below 1 μΜ whereas the IC50 values of Simvastatin (Fig. 2C), Atorvastatin (Fig. 2D), Lovastatin (Fig. 2E) were generally comprised between 1 and 3μΜ. Rosuvastatin (Fig. 2F) revealed a significant antifibrotic activity but only at the highest doses and Pravastatin (Fig. 2G) was found inactive alone at the tested doses. It is noteworthy that the antifibrotic properties of the various statin family members do not seem to be related to their lipid lowering capacity. For example, Rosuvastatin, which is considered the most potent statin for HMG_CoA reductase Inhibition (IC50=5.4 nM; (McKenney, 2003) revealed weak antifibrotic properties.
In order to evaluate if a combination of statin with NTZ or TZ could reduce fibrosis in a synergistic manner, combination matrix experiments were performed in TGF -induced HSCs. Briefly, NTZ or TZ and statin solutions were serially diluted in a checkerboard format generating a 36 combinations matrix covering a large panel of statin/NTZ or statin/TZ ratios. Synergy was first determined by calculating Excess Over Bliss scores. In order to rank the different statins based on their synergism, the sum of the EOB scores obtained for each statin was also calculated. These experiments revealed that NTZ could synergize with all statins, but not with the same potency, to reduce a-SMA production in activated HSCs.
The best synergy was obtained with NTZ in combination with Pitavastatin (total EOB score of 337), followed by Simvastatin (total EOB score of 255), Fluvastatin (total EOB score of 141 ),
Lovastatin (total EOB score of 91 ), Pravastatin (total EOB score of 88), and Atorvastatin (total EOB score of 73) (Fig. 4B, 5B, 6B, 7B and 8B). Positive EOB score were obtained only for a few NTZ/ROSU ratios (data not shown) indicating a synergy, but weaker, comparatively to the other NTZ/statin combinations. To validate the synergism, the experimental values corresponding tohighthe EOB score for each NTZ/statin combination were plotted in a bar graph (Fig. 4C, 5C, 6C, 7C, and 8C).
These graphs illustrate that the combination of NTZ with Pitavastatin, Simvastatin, Fluvastatin, Lovastatin, Atorvastatin and Pravastatin show a superior antifibrotic effect that is statistically significant compared to the highest single agent (NTZ or statin). The most impressive examples are represented with Pitavastatin, Simvastatin, or Fluvastatin in which the single agents provide a weak antifibrotic activity (-10 to 20% inhibition) at suboptimal doses, however, when combined with NTZ, reach an inhibition of a-SMA in the order of 60 to 70%. Tizoxanide, the active metabolite of NTZ, was also evaluated in combination with the statins that revealed the best synergism with NTZ, namely Pitavastatin, Simvastatin and Fluvastatin. As observed with NTZ, the TZ metabolite also synergized with these 3 statins (an example with Fluvastatin is shown in Fig.9).
In addition to their antifibrotic properties, it was found that a combination of NTZ at 30 mg/kg/day with Simvastatin at 10 mg/kg/day synergized to prevent the occurrence of altered levels of circulating bile acids in a model of CCI4-induced liver injury (Fig.10). In conclusion, the applicant has discovered unexpected anticholestatic and antifibrotic activities for a combination of a compound of Formula (I) statins. These results suggest that a combination of a compound of Formula (I) with a statin can be synergistic and can provide therapeutic benefits in multiple types of cholestatic and fibrotic diseases.
REFERENCES
Broekhuysen, J., A. Stockis, et al. (2000). "Nitazoxanide: pharmacokinetics and metabolism in man." Int J Clin Pharmacol Ther 38(8): 387-394.
Chong, L. W., Y. C. Hsu, et al. (2015). "Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells." BMC Gastroenterol 15: 22.
de Carvalho, L. P. S., C. M. Darby, et al. (201 1 ). "Nitazoxanide disrupts membrane potential and intrabacterial pH homeostasis of Mycobacterium tuberculosis." ACS Med. Chem.
Lett. 2(Copyright (C) 2015 American Chemical Society (ACS). All Rights Reserved.): 849-854.
Di Santo, N. and J. Ehrisman (2014). "A functional perspective of nitazoxanide as a potential anticancer drug." Mutat. Res., Fundam. Mol. Mech. Mutagen. 768(Copyright (C) 2015 American Chemical Society (ACS). All Rights Reserved.): 16-21 .
Dubreuil, L, I. Houcke, et al. (1996). "In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms." Antimicrob. Agents Chemother. 40(Copyright (C) 2015 American Chemical Society (ACS). All Rights Reserved.): 2266-2270.
Finegold, S. M., D. Molitoris, et al. (2009). "Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora." Antimicrob. Agents Chemother.
53(Copyright (C) 2015 American Chemical Society (ACS). All Rights Reserved.): 281 - 286.
Fox, L. M. and L. D. Saravolatz (2005). "Nitazoxanide: a new thiazolide antiparasitic agent."
Clin. Infect. Pis. 40(Copyright (C) 2015 American Chemical Society (ACS). All Rights Reserved.): 1 173-1 180.
Hemphill, A., J. Mueller, et al. (2006). "Nitazoxanide, a broad-spectrum thiazolide anti- infective agent for the treatment of gastrointestinal infections." Expert Opin. Pharmacother. 7(Copyright (C) 2015 American Chemical Society (ACS). All Rights
Reserved.): 953-964.
Hoffman, P. S., G. Sisson, et al. (2007). "Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni." Antimicrob. Agents Chemother. 51 (Copyright (C) 2015 American Chemical Society (ACS). All Rights Reserved.): 868-876.
Ji, H., H. Tang, et al. (2014). "Rho/Rock cross-talks with transforming growth factor- beta/Smad pathway participates in lung fibroblast-myofibroblast differentiation."
Biomed Rep 2(6): 787-792.
Kavalipati, N., J. Shah, et al. (2015). "Pleiotropic effects of statins." Indian J Endocrinol Metab 19(5): 554-562.
Kendall, R. T. and C. A. Feghali-Bostwick (2014). "Fibroblasts in fibrosis: novel roles and mediators." Front Pharmacol 5: 123.
Leask, A. (2007). "TGFbeta, cardiac fibroblasts, and the fibrotic response." Cardiovasc Res
74(2): 207-212.
Leask, A. and D. J. Abraham (2004). "TGF-beta signaling and the fibrotic response." FASEB J 18(7): 816-827.
Marrone, G., R. Maeso-Diaz, et al. (2015). "KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins." Gut 64(9): 1434-1443.
McFarlane, S. I., R. Muniyappa, et al. (2002). "Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond." J Clin Endocrinol Metab 87(4): 1451 -1458.
McKenney, J. M. (2003). "Pharmacologic characteristics of statins." Clin Cardiol 26(4 Suppl 3): III32-38.
Megraudd, F., A. Occhialini, et al. (1998). "Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole." Antimicrob. Agents
Chemother. 42(Copyright (C) 2015 American Chemical Society (ACS). All Rights Reserved.): 2836-2840.
Miyaki, T., S. Nojiri, et al. (201 1 ). "Pravastatin inhibits hepatic steatosis and fibrosis in nonalcoholic steatohepatitis model rats." Hepatol Res 41 (4): 375-385.
Pankuch, G. A. and P. C. Appelbaum (2006). "Activities of tizoxanide and nitazoxanide compared to those of five other thiazolides and three other agents against anaerobic species." Antimicrob. Agents Chemother. 50(Copyright (C) 2015 American Chemical Society (ACS). All Rights Reserved.): 1 1 12-1 1 17.
Rombouts, K., E. Kisanga, et al. (2003). "Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells." J Hepatol 38(5): 564-
572.
Rosenbloom, J., F. A. Mendoza, et al. (2013). "Strategies for anti-fibrotic therapies." Biochim
Biophvs Acta 1832(7): 1088-1 103.
Rossignol, J.-F. (2014). "Nitazoxanide: A first-in-class broad-spectrum antiviral agent." Antiviral Res. 110(Copyright (C) 2015 American Chemical Society (ACS). All Rights
Reserved.): 94-103.
Rossignol, J. F. and R. Cavier (1975). 2-Benzamido-5-nitrothiazoles, S.P.R.L. Phavic, Belg. . 1 1 pp.
Rossignol, J. F. and H. Maisonneuve (1984). "Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana infections." Am J Trop Med Hvg 33(Copyright (C) 2015 U.S. National Library of Medicine.): 51 1 -512.
Wang, C. Y., P. Y. Liu, et al. (2008). "Pleiotropic effects of statin therapy: molecular mechanisms and clinical results." Trends Mol Med 14(1 ): 37-44.
Wang, W., C. Zhao, et al. (2013). "Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis." PLoS One 8(10): e76538.
Watts, K. L., E. M. Sampson, et al. (2005). "Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts." Am J Respir Cell Mol Biol 32(4):
290-300.
Yeganeh, B., E. Wiechec, et al. (2014). "Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease." Pharmacol
Ther 143(1 ): 87-1 10.
Zhou, Q. and J. K. Liao (2009). "Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy." Curr Pharm Pes 15(5): 467-478.
Zhu, B., A. Q. Ma, et al. (2013). "Atorvastatin attenuates bleomycin-induced pulmonary fibrosis via suppressing iNOS expression and the CTGF (CCN2)/ERK signaling pathway." Int J Mol Sci 14(12): 24476-24491.
Claims (13)
1 . A synergistic combination of
(i) Nitazoxanide (NTZ), a deuterated derivative of NTZ (NTZ-D), Tizoxanide (TZ) or
Tizoxanide glucuronide (TZG), or a pharmaceutically acceptable salt of NTZ, NTZ-D, TZ or TZG; and
(ii) at least one statin.
2. The synergistic combination of claim 1 , in the form of a pharmaceutical composition or of a kit-of-parts.
3. The synergistic combination of claim 1 or 2, wherein the at least one specific statin is selected in the group consisting of mevastatin, cerivastatin, pitavastatin, fluvastatin, simvastatin, atorvastatin, lovastatin, rosuvastatin, and pravastatin.
4. The synergistic combination according to claim 3 wherein the statin is selected in the group consisting of pitavastatin, fluvastatin and simvastatin.
5. The synergistic combination according to any one of claims 1 to 4, further comprising at least one therapeutically active agent with known antifibrotic activity selected from pirfenidone or receptor tyrosine kinase inhibitors (RTKIs) such as Nintedanib, Sorafenib and other RTKIs, or angiotensin II (AT1 ) receptor blockers, or CTGF inhibitor, or any antifibrotic compound susceptible to interfere with the TGF3 and BMP-activated pathways including activators of the latent TGF3 complex such as MMP2, MMP9, THBS1 or cell-surface integrins, TGF3 receptors type I (TGFBRI) or type II (TGFBRII) and their ligands such as TGF3, Activin, inhibin, Nodal, anti-Mijllerian hormone, GDFs or BMPs, auxiliary co-receptors (also known as type III receptors), or components of the SMAD-dependent canonical pathway including regulatory or inhibitory SMAD proteins, or members of the SMAD- independent or non-canonical pathways including various branches of MAPK signaling, TAK1 , Rho-like GTPase signaling pathways, phosphatidylinositol-3 kinase/AKT pathways, TGF3-induced EMT process, or canonical and non-canonical Hedgehog signaling pathways including Hh ligands or target genes, or any members of the WNT, or Notch pathways which are susceptible to influence TGF3.
6. The synergistic combination according to any one of claims 1 to 5, further comprising at least one therapeutically active agent selected from JAK/STAT inhibitors and other antiinflammatory and/or immunosuppressant agents.
7. The synergistic combination according to claim 6, wherein the therapeutically active agent is selected from glucocorticoids, NSAIDS, cyclophosphamide, nitrosoureas, folic acid analogs, purine analogs, pyrimidine analogs, methotrexate, azathioprine, mercaptopurine, ciclosporin, myriocin, tacrolimus, sirolimus, mycophenolic acid derivatives, fingolimod and other sphingosine-1 -phosphate receptor modulators, monoclonal and/or polyclonal antibodies against such targets as proinflammatory cytokines and proinflammatory cytokine receptors, T-cell receptor and integrins.
8. The synergistic combination according to any one of claims 1 to 7, for use as a medicament.
9. The synergistic combination according to any one of claims 1 to 7, for use in a method for treating a cholestatic or fibrotic disorder.
10. The synergistic combination for use according to claim 9, wherein the fibrotic disorder is selected in the group consisting of liver, gut, kidney, skin, epidermis, endodermis, muscle, tendon, cartilage, heart, pancreas, lung, uterus, nervous system, testis, penis, ovary, adrenal gland, artery, vein, colon, intestine (e.g. small intestine), biliary tract, soft tissue (e.g. mediastinum or retroperitoneum), bone marrow, joint eye, and stomach fibrosis.
1 1 . The synergistic combination for use according to claim 9 or 10, wherein the fibrotic disorder is selected in the group consisting of liver, gut, lung, heart, kidney, muscle, skin, soft tissue, bone marrow, intestinal, and joint fibrosis.
12. The synergistic comibination for use according to any one of claims 9 to 1 1 , wherein the fibrotic disorder is selected in the group consisting of non-alcoholic steatohepatitis (NASH), pulmonary fibrosis, idiopathic pulmonary fibrosis, skin fibrosis, eye fibrosis, endomyocardial fibrosis, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis, proliferative fibrosis, neoplastic fibrosis, lung fibrosis consecutive to chronic inflammatory airway disease (COPD, asthma, emphysema, smoker's lung, tuberculosis), alcohol or drug-induced liver fibrosis, liver cirrhosis, infection-induced liver fibrosis, radiation or chemotherapeutic-induced fibrosis, nephrogenic systemic fibrosis, Crohn's disease,
ulcerative colitis, keloid, old myocardial infarction, scleroderma/systemic sclerosis, arthrofibrosis, some forms of adhesive capsulitis, chronic fibrosing cholangiopathies such as Primary Sclerosing Cholangitis (PSC), Primary Biliary Cholangitis (PBC), biliary atresia, familial intrahepatic cholestasis type 3 (PFIC3), peri-implantational fibrosis and asbestosis.
13. The synergistic combination for use according to any one of claims 9 to 1 1 , wherein the cholestatic disorder is selected in the group consisting of primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), Intrahepatic Cholestasis of Pregnancy, Progressive Familial Intrahepatic Cholestasis, Biliary atresia, Cholelithiasis, Infectious Cholangitis, Cholangitis associated with Langerhans cell histiocytosis, Alagille syndrome, Nonsyndromic ductal paucity, Drug-induced cholestasis, and Total parenteral nutrition-associated cholestasis.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16305427 | 2016-04-11 | ||
EP16305427.3 | 2016-04-11 | ||
PCT/EP2017/055880 WO2017178173A1 (en) | 2016-04-11 | 2017-03-13 | Methods of treatment for cholestatic and fibrotic diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2017249603A1 AU2017249603A1 (en) | 2018-10-18 |
AU2017249603B2 true AU2017249603B2 (en) | 2022-12-01 |
Family
ID=55755537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2017249603A Active AU2017249603B2 (en) | 2016-04-11 | 2017-03-13 | Methods of treatment for cholestatic and fibrotic diseases |
Country Status (16)
Country | Link |
---|---|
US (1) | US20170290813A1 (en) |
EP (1) | EP3442518B1 (en) |
JP (1) | JP7134092B2 (en) |
KR (1) | KR102410951B1 (en) |
CN (1) | CN109152760B (en) |
AU (1) | AU2017249603B2 (en) |
BR (1) | BR112018069682A2 (en) |
CA (1) | CA3019205A1 (en) |
CO (1) | CO2018012180A2 (en) |
EA (1) | EA201892297A1 (en) |
IL (1) | IL262186B2 (en) |
MX (1) | MX2018012285A (en) |
PH (1) | PH12018502161A1 (en) |
SG (1) | SG11201808540SA (en) |
WO (1) | WO2017178173A1 (en) |
ZA (1) | ZA201807390B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201808402RA (en) | 2016-04-11 | 2018-10-30 | Genfit | Methods of treatment for cholestatic and fibrotic diseases |
CN110418641A (en) * | 2017-02-24 | 2019-11-05 | 基恩菲特公司 | Pharmaceutical composition for combination treatment |
MX2019010322A (en) | 2017-03-13 | 2019-10-21 | Genfit | Pharmaceutical compositions for combination therapy. |
CN110241201B (en) * | 2019-02-22 | 2021-02-09 | 无锡市妇幼保健院 | Serum/plasma LncRNA marker ASO3480 related to ICP auxiliary diagnosis and application thereof |
WO2023122869A1 (en) * | 2021-12-27 | 2023-07-06 | 浙江海正药业股份有限公司 | Use of rosuvastatin calcium in preparation of drug for preventing and treating cholestasis and liver fibrosis |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013082469A2 (en) * | 2011-12-02 | 2013-06-06 | University Of Vermont And State Agricultural College | Methods and compositions for treating infections |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0619500D0 (en) * | 2006-10-03 | 2006-11-08 | Univ Keele | Treatment of fibrosis |
WO2008124384A2 (en) * | 2007-04-03 | 2008-10-16 | Aegerion Pharmaceuticals, Inc. | Combinations of mtp inhibitors with cholesterol absorption inhibitors or interferon for treating hepatitis c |
US20110177999A1 (en) * | 2007-08-09 | 2011-07-21 | Vertex Pharmaceuticals Incorporated | Therapeutic Combinations Useful in Treating CFTR Related Diseases |
EP2395840B1 (en) * | 2009-02-13 | 2020-04-15 | Romark Laboratories, L.C. | Controlled release pharmaceutical formulations of nitazoxanide |
US9974767B2 (en) | 2014-07-14 | 2018-05-22 | University Of Washington | Statins in the treatment of muscular dystrophies and myopathies |
-
2017
- 2017-03-13 MX MX2018012285A patent/MX2018012285A/en unknown
- 2017-03-13 EP EP17711119.2A patent/EP3442518B1/en active Active
- 2017-03-13 EA EA201892297A patent/EA201892297A1/en unknown
- 2017-03-13 IL IL262186A patent/IL262186B2/en unknown
- 2017-03-13 KR KR1020187032696A patent/KR102410951B1/en active IP Right Grant
- 2017-03-13 AU AU2017249603A patent/AU2017249603B2/en active Active
- 2017-03-13 SG SG11201808540SA patent/SG11201808540SA/en unknown
- 2017-03-13 CN CN201780023051.8A patent/CN109152760B/en active Active
- 2017-03-13 BR BR112018069682A patent/BR112018069682A2/en not_active Application Discontinuation
- 2017-03-13 JP JP2018553087A patent/JP7134092B2/en active Active
- 2017-03-13 US US15/457,402 patent/US20170290813A1/en not_active Abandoned
- 2017-03-13 CA CA3019205A patent/CA3019205A1/en active Pending
- 2017-03-13 WO PCT/EP2017/055880 patent/WO2017178173A1/en active Application Filing
-
2018
- 2018-10-08 PH PH12018502161A patent/PH12018502161A1/en unknown
- 2018-11-05 ZA ZA2018/07390A patent/ZA201807390B/en unknown
- 2018-11-13 CO CONC2018/0012180A patent/CO2018012180A2/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013082469A2 (en) * | 2011-12-02 | 2013-06-06 | University Of Vermont And State Agricultural College | Methods and compositions for treating infections |
Also Published As
Publication number | Publication date |
---|---|
BR112018069682A2 (en) | 2019-01-29 |
KR102410951B1 (en) | 2022-06-20 |
JP7134092B2 (en) | 2022-09-09 |
KR20180129936A (en) | 2018-12-05 |
PH12018502161A1 (en) | 2019-07-15 |
SG11201808540SA (en) | 2018-10-30 |
IL262186B1 (en) | 2023-06-01 |
IL262186A (en) | 2018-11-29 |
CA3019205A1 (en) | 2017-10-19 |
EA201892297A1 (en) | 2019-07-31 |
ZA201807390B (en) | 2019-08-28 |
CO2018012180A2 (en) | 2019-08-20 |
CN109152760A (en) | 2019-01-04 |
MX2018012285A (en) | 2019-02-07 |
CN109152760B (en) | 2022-09-23 |
JP2019513760A (en) | 2019-05-30 |
AU2017249603A1 (en) | 2018-10-18 |
IL262186B2 (en) | 2023-10-01 |
WO2017178173A1 (en) | 2017-10-19 |
EP3442518B1 (en) | 2024-01-17 |
US20170290813A1 (en) | 2017-10-12 |
EP3442518A1 (en) | 2019-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10117855B2 (en) | Methods of treatment for cholestatic and fibrotic diseases | |
AU2017249603B2 (en) | Methods of treatment for cholestatic and fibrotic diseases | |
US20220323422A1 (en) | Methods of treatment for cholestatic and fibrotic diseases | |
US10653678B2 (en) | Methods of treatment for cholestatic and fibrotic diseases | |
US10905680B2 (en) | Methods of treatment for cholestatic and fibrotic diseases | |
EA043787B1 (en) | USE OF A COMBINATION OF NITAZOXANIDE OR TIZOXANIDE WITH A STATIN FOR THE TREATMENT OF CHOLESTATIC AND FIBROTIC DISORDERS | |
NZ785186A (en) | Methods of treatment for cholestatic and fibrotic diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |